BIO-RAD LABORATORIES, INC. - Quarter Report: 2019 September (Form 10-Q)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q



(Mark One)
☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934



For the quarterly period ended	September 30, 2019



☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from______________to __________



Commission file number	1-7928

BIO-RAD LABORATORIES, INC.

(Exact name of registrant as specified in its charter)



Delaware		94-1381833
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)
1000 Alfred Nobel Drive,	Hercules,	California	94547
(Address of principal executive offices)			(Zip Code)



(510)	724-7000

(Registrant's telephone number, including area code)

No Change

(Former name, former address and former fiscal year, if changed since last report.)

Securities registered pursuant to Section 12(b) of the Act:



Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Class A Common Stock, Par Value $0.0001 per share	BIO	New York Stock Exchange
Class B Common Stock, Par Value $0.0001 per share	BIOb	New York Stock Exchange



Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days.	Yes	☒	No	☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232,405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit files).



Yes	☒	No	☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act. (Check one):



Large accelerated filer	☒	Accelerated filer	☐
Non-accelerated filer	☐	Smaller reporting company	☐
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).



Yes	☐	No	☒

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.



Common Shares Outstanding at October 23, 2019:	Class A -	24,836,205	Class B -	5,098,637

BIO-RAD LABORATORIES, INC.

FORM 10-Q SEPTEMBER 30, 2019

TABLE OF CONTENTS



Part I – Financial Information	4
Item 1. Financial Statements	4
Condensed Consolidated Balance Sheets	4
Condensed Consolidated Statements of Income	6
Condensed Consolidated Statements of Comprehensive Income	7
Condensed Consolidated Statements of Cash Flows	8
Condensed Consolidated Statements of Changes in Stockholders' Equity	9
Notes to Condensed Consolidated Financial Statements	11
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations	34
Item 3. Quantitative and Qualitative Disclosures about Market Risk	41
Item 4. Controls and Procedures	41
Part II – Other Information	42
Item 1. Legal Proceedings	42
Item 1A. Risk Factors	42
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	56
Item 3. Defaults Upon Senior Securities	57
Item 4. Mine Safety Disclosures	57
Item 5. Other Information	57
Item 6. Exhibits	58
Signatures	59

INFORMATION RELATING TO FORWARD-LOOKING STATEMENTS

Other than statements of historical fact, statements made in this report include forward-looking statements, such as statements with respect to our future financial performance, operating results, plans and objectives that involve risk and uncertainties. Forward-looking statements generally can be identified by the use of forward-looking terminology, such as “believe,” “expect,” “anticipate,” “may,” “will,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. We have based these forward-looking statements on our current expectations and projections about future events. However, actual results may differ materially from those currently anticipated depending on a variety of risk factors including, but not limited to, those identified under “Part II, Item 1A, Risk Factors” of this Quarterly Report on Form 10-Q. We caution you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

PART I – FINANCIAL INFORMATION

Item 1. Financial Statements

BIO-RAD LABORATORIES, INC.

Condensed Consolidated Balance Sheets

(In thousands, except share data)



	September 30, 2019			December 31, 2018
ASSETS:	(Unaudited)
Cash and cash equivalents	$	561,071		$	431,526
Short-term investments	418,177			413,270
Restricted investments	5,560			5,560
Accounts receivable, less allowance for doubtful accounts of $23,147 at 2019 and $26,713 at 2018	356,025			392,443
Inventories:
Raw materials	112,432			108,008
Work in process	141,268			145,051
Finished goods	334,287			330,756
Total inventories	587,987			583,815
Prepaid expenses	109,584			187,249
Other current assets	9,228			9,615
Total current assets	2,047,632			2,023,478
Property, plant and equipment	1,347,364			1,326,829
Less: accumulated depreciation and amortization	(851,488		)	(818,139		)
Property, plant and equipment, net	495,876			508,690
Operating lease right-of-use assets	217,516			—
Goodwill, net	264,084			219,770
Purchased intangibles, net	146,965			133,123
Other investments	3,931,715			2,655,709
Other assets	73,328			70,298
Total assets	$	7,177,116		$	5,611,068

The accompanying notes are an integral part of these condensed consolidated financial statements.

BIO-RAD LABORATORIES, INC.

Condensed Consolidated Balance Sheets

(continued)

(In thousands, except share data)



	September 30, 2019			December 31, 2018
LIABILITIES AND STOCKHOLDERS’ EQUITY:	(Unaudited)
Accounts payable, accrued payroll and employee benefits	$	249,835		$	265,960
Current maturities of long-term debt and notes payable	1,769			493
Income and other taxes payable	35,252			56,188
Current operating lease liabilities	33,694			—
Other current liabilities	113,490			128,154
Total current liabilities	434,040			450,795
Long-term debt, net of current maturities	437,808			438,937
Deferred income taxes	838,001			553,239
Operating lease liabilities	192,600			—
Other long-term liabilities	143,475			147,766
Total liabilities	2,045,924			1,590,737

Stockholders’ equity:
Class A common stock, shares issued 24,942,773 and 24,884,265 at 2019 and 2018, respectively; shares outstanding 24,834,725 and 24,704,772 at 2019 and 2018, respectively	2			2
Class B common stock, shares issued 5,100,137 and 5,096,421 at 2019 and 2018, respectively; shares outstanding 5,100,137 and 5,095,504 at 2019 and 2018, respectively	1			1
Additional paid-in capital	396,432			394,342
Class A treasury stock at cost, 108,048 and 179,493 shares at 2019 and 2018, respectively	(30,443		)	(49,040		)
Class B treasury stock at cost, 0 and 917 shares at 2019 and 2018, respectively	—			(89		)
Retained earnings	4,917,313			3,722,073
Accumulated other comprehensive loss	(152,113		)	(46,958		)
Total stockholders’ equity	5,131,192			4,020,331
Total liabilities and stockholders’ equity	$	7,177,116		$	5,611,068

The accompanying notes are an integral part of these condensed consolidated financial statements.

BIO-RAD LABORATORIES, INC.

Condensed Consolidated Statements of Income

(In thousands, except per share data)

(Unaudited)



	Three Months Ended						Nine Months Ended
	September 30,						September 30,
	2019			2018			2019			2018

Net sales	$	560,633		$	545,138		$	1,687,231		$	1,672,568
Cost of goods sold	253,607			258,422			760,674			781,982
Gross profit	307,026			286,716			926,557			890,586
Selling, general and administrative expense	201,622			201,196			610,460			620,751
Research and development expense	47,944			49,245			145,641			146,122
Income from operations	57,460			36,275			170,456			123,713
Interest expense	5,525			6,064			17,352			17,823
Foreign currency exchange losses, net	898			672			3,411			1,911
Change in fair market value of equity securities	390,620			(318,007		)	(1,384,999		)	(1,420,339		)
Other (income) expense, net	(4,367		)	(2,585		)	(26,959		)	(29,588		)
(Loss) income before income taxes	(335,216		)	350,131			1,561,651			1,553,906
Benefit from (provision for) income taxes	76,400			(80,805		)	(356,462		)	(359,763		)
Net (loss) income	$	(258,816	)	$	269,326		$	1,205,189		$	1,194,143

Basic (loss) earnings per share:
Net (loss) income per basic share	$	(8.68	)	$	9.02		$	40.42		$	40.04
Weighted average common shares - basic	29,831			29,863			29,815			29,822

Diluted (loss) earnings per share:
Net (loss) income per diluted share	$	(8.68	)	$	8.89		$	39.97		$	39.50
Weighted average common shares - diluted	29,831			30,292			30,149			30,234

The accompanying notes are an integral part of these condensed consolidated financial statements.

BIO-RAD LABORATORIES, INC.

Condensed Consolidated Statements of Comprehensive Income

(In thousands)

(Unaudited)



	Three Months Ended						Nine Months Ended
	September 30,						September 30,
	2019			2018			2019			2018
Net (loss) income	$	(258,816	)	$	269,326		$	1,205,189		$	1,194,143
Other comprehensive income (loss):
Foreign currency translation adjustments	(103,332		)	(13,556		)	(109,888		)	(91,128		)
Foreign other post-employment benefits adjustments, net of income taxes	359			105			501			1,281
Net holding gain (loss) on equity securities and net unrealized holding gain (loss) on available-for-sale investments, net of income taxes	433			(138		)	4,232			(1,989		)
Other comprehensive income (loss), net of income taxes	(102,540		)	(13,589		)	(105,155		)	(91,836		)
Comprehensive (loss) income	$	(361,356	)	$	255,737		$	1,100,034		$	1,102,307

The accompanying notes are an integral part of these condensed consolidated financial statements.

BIO-RAD LABORATORIES, INC.

Condensed Consolidated Statements of Cash Flows

(In thousands, unaudited)



	Nine Months Ended
	September 30,
	2019			2018
Cash flows from operating activities:
Cash received from customers	$	1,716,486		$	1,715,960
Cash paid to suppliers and employees	(1,392,653		)	(1,494,794		)
Interest paid, net	(11,381		)	(11,721		)
Income tax payments, net	(42,634		)	(57,840		)
Investment proceeds and miscellaneous receipts, net	28,092			21,601
Proceeds from forward foreign exchange contracts, net	185			7,279
Net cash provided by operating activities	298,095			180,485
Cash flows from investing activities:
Capital expenditures	(76,934		)	(75,951		)
Proceeds from dispositions of property, plant and equipment	85			4,273
Proceeds from divestiture of a product line	—			6,964
(Payments for) proceeds from acquisitions, net of cash received	(75,811		)	266
Recovery of (payments for) purchases of intangible assets	7,383			(3		)
Payments for purchases of marketable securities and investments	(266,839		)	(286,826		)
Proceeds from sales of marketable securities and investments	83,315			60,488
Proceeds from maturities of marketable securities and investments	181,108			158,622
Net cash used in investing activities	(147,693		)	(132,167		)
Cash flows from financing activities:
Payments on long-term borrowings	(487		)	(1,595		)
Payments for credit agreement renewal fees	(486		)	—
Payments of contingent consideration	(2,477		)	(2,078		)
Proceeds from issuances of common stock for share-based compensation	9,740			10,858
Tax payments from net share settlement	(8,096		)	(8,862		)
Proceeds from reissuances of treasury stock for share-based compensation, net	3,831			—
Payments for purchases of treasury stock	(20,000		)	—
Net cash used in financing activities	(17,975		)	(1,677		)
Effect of foreign exchange rate changes on cash	(3,239		)	3,965
Net increase in cash, cash equivalents, and restricted cash	129,188			50,606
Cash, cash equivalents, and restricted cash at beginning of period	434,164			384,983
Cash, cash equivalents, and restricted cash at end of period	$	563,352		$	435,589

The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the Condensed Consolidated Balance Sheets that agrees to the same amounts shown in the Condensed Consolidated Statements of Cash Flows (in thousands):



	September 30, 2019		September 30, 2018
Cash and cash equivalents	$	561,071	$	434,517
Restricted cash included in Other current assets	100		102
Restricted cash included in Other assets	2,181		970
Total cash, cash equivalents, and restricted cash shown in the Condensed Consolidated Statements of Cash Flows	$	563,352	$	435,589

These restricted cash items are primarily related to performance guarantees.

The accompanying notes are an integral part of these condensed consolidated financial statements.

BIO-RAD LABORATORIES, INC.

Condensed Consolidated Statements of Changes in Stockholders' Equity

(In thousands)

(Unaudited)



	Common Stock		Additional Paid-in Capital			Treasury Stock			Retained Earnings			Accumulated Other Comprehensive Income (Loss)			Total Stockholders' Equity
Balance at December 31, 2018	$	3	$	394,342		$	(49,129	)	$	3,722,073		$	(46,958	)	$	4,020,331
Net income	—		—			—			865,195			—			865,195
Other comprehensive loss, net of tax	—		—			—			—			(34,007		)	(34,007		)
Stock compensation expense	—		8,505			—			—			—			8,505
Reissuance of treasury stock	—		—			5,398			(1,567		)	—			3,831
Balance at March 31, 2019	$	3	$	402,847		$	(43,731	)	$	4,585,701		$	(80,965	)	$	4,863,855
Net income	—		—			—			598,810			—			598,810
Other comprehensive income, net of tax	—		—			—			—			31,392			31,392
Issuance of common stock	—		(64		)	—			—			—			(64		)
Stock compensation expense	—		7,818			—			—			—			7,818
Purchase of treasury stock	—		—			(15,001		)	—			—			(15,001		)
Balance at June 30, 2019	$	3	$	410,601		$	(58,732	)	$	5,184,511		$	(49,573	)	$	5,486,810
Net loss	—		—			—			(258,816		)	—			(258,816		)
Other comprehensive loss, net of tax	—		—			—			—			(102,540		)	(102,540		)
Issuance of common stock	—		1,708			—			—			—			1,708
Stock compensation expense	—		9,029			—			—			—			9,029
Purchase of treasury stock	—		—			(4,999		)	—			—			(4,999		)
Reissuance of treasury stock	—		(24,906		)	33,288			(8,382		)	—			—
Balance at September 30, 2019	$	3	$	396,432		$	(30,443	)	$	4,917,313		$	(152,113	)	$	5,131,192

The accompanying notes are an integral part of these condensed consolidated financial statements.

BIO-RAD LABORATORIES, INC.

Condensed Consolidated Statements of Changes in Stockholders' Equity

(continued)

(In thousands)

(Unaudited)



	Common Stock		Additional Paid-in Capital			Treasury Stock			Retained Earnings		Accumulated Other Comprehensive Income (Loss)			Total Stockholders' Equity
Balance at December 31, 2017	$	3	$	361,231		$	(217	)	$	1,830,439	$	738,794		$	2,930,250
Adoption of new accounting guidance									1,526,019		(679,257		)	846,762
Net income	—		—			—			656,774		—			656,774
Other comprehensive income, net of tax	—		—			—			—		44,548			44,548
Issuance of common stock	—		3,872			—			—		—			3,872
Stock compensation expense	—		5,885			—			—		—			5,885
Balance at March 31, 2018	$	3	$	370,988		$	(217	)	$	4,013,232	$	104,085		$	4,488,091
Net income	—		—			—			268,043		—			268,043
Other comprehensive loss, net of tax	—		—			—			—		(122,795		)	(122,795		)
Issuance of common stock	—		(598		)	—			—		—			(598		)
Stock compensation expense	—		6,205			—			—		—			6,205
Balance at June 30, 2018	$	3	$	376,595		$	(217	)	$	4,281,275	$	(18,710	)	$	4,638,946
Net income	—		—			—			269,326		—			269,326
Other comprehensive loss, net of tax	—		—			—			—		(13,589		)	(13,589		)
Issuance of common stock	—		(1,278		)	—			—		—			(1,278		)
Stock compensation expense	—		7,076			—			—		—			7,076
Balance at September 30, 2018	$	3	$	382,393		$	(217	)	$	4,550,601	$	(32,299	)	$	4,900,481

The accompanying notes are an integral part of these condensed consolidated financial statements.

BIO-RAD LABORATORIES, INC

Notes to Condensed Consolidated Financial Statements

(Unaudited)

1.BASIS OF PRESENTATION AND USE OF ESTIMATES

Basis of Presentation

In this report, “Bio-Rad,” “we,” “us,” “the Company” and “our” refer to Bio-Rad Laboratories, Inc. and its subsidiaries. The accompanying unaudited condensed consolidated financial statements of Bio-Rad have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) and reflect all adjustments which are, in the opinion of management, necessary to fairly state the results of the interim periods presented. All such adjustments are of a normal recurring nature. Results for the interim period are not necessarily indicative of the results for the entire year. The condensed consolidated balance sheet at December 31, 2018 has been derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by GAAP for complete financial statements. The condensed consolidated financial statements should be read in conjunction with the notes to the consolidated financial statements contained in our Annual Report on Form 10-K for the year ended December 31, 2018.

We evaluate subsequent events and the evidence they provide about conditions existing at the date of the balance sheet as well as conditions that arose after the balance sheet date but through the date the financial statements are issued. The effects of conditions that existed at the balance sheet date are recognized in the financial statements. Events and conditions arising after the balance sheet date but before the financial statements are issued are evaluated to determine if disclosure is required to keep the financial statements from being misleading. To the extent such events and conditions exist, disclosures are made regarding the nature of events and the estimated financial effects of those events and conditions.

Use of Estimates

The preparation of the condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingencies at the date of the financial statements as well as the reported amounts of revenues and expenses during the reporting periods. Bio-Rad bases its estimates on historical experience and on various other market-specific and other relevant assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.

Revenue Recognition

On January 1, 2018, we adopted Accounting Standards Codification ("ASC") 606, "Revenue from Contracts with Customers," using the modified retrospective method applied to those contracts that were not completed as of January 1, 2018. We recorded a net reduction to opening retained earnings of $0.1 million as of January 1, 2018 due to the cumulative impact of adopting ASC 606 with the impact primarily related to a customer loyalty program in the United States for which the resulting non-cash consideration is treated as variable consideration under the new revenue recognition accounting standard.

We recognize revenue from operations through the sale of products, services, and rental of instruments. Revenue from contracts with customers is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration we expect to receive in exchange for those products or services. We enter into contracts that can include various combinations of products and services, which are generally accounted for as distinct performance obligations. Revenue is recognized net of any taxes collected from customers (sales tax, value added tax, etc.), which are subsequently remitted to government authorities.

Our contracts from customers often include promises to transfer multiple products and services to a customer. Determining whether products and services are considered distinct performance obligations that should be accounted for separately versus together may require significant judgment, and may or may not impact the timing of revenue recognition. Revenue associated with equipment that requires factory installation is not recorded until installation is complete and customer acceptance, if required, has occurred. Certain equipment requires installation due to the fact that the instruments are being operated in a clinical/laboratory environment, and the installation services could result in modification of the equipment in order to ensure that the instruments are working according to specifications of the customer which are subject to validation tests upon completion of the installation. In these arrangements, which require factory installation, the delivery of the equipment and the installation are separate performance obligations. We will recognize the transaction price allocated to the equipment only upon customer acceptance, as the transfer of control has occurred in relation to the equipment at that point in time as the customer has the ability to direct the use of and obtain substantially all of the remaining benefits from the asset. The transaction price allocated to the installation services is also recognized upon completion of the services because without the completion of the installation services and related customer acceptance the customer cannot receive any of the benefits of the service.

At the time revenue is recognized, a provision is recognized for estimated product returns as this right is considered variable consideration. Accordingly, when product revenues are recognized, the transaction price is reduced by the estimated amount of product returns.

Service revenues on extended warranty contracts are recognized ratably over the life of the service agreement as a stand-ready performance obligation. For arrangements that include a combination of products and services, transaction prices are allocated to performance obligations based on stand-alone selling prices. The method used to determine the stand-alone selling prices for service revenues is based on the observable prices when the services have been sold separately.

In those instances where the timing of revenue recognition differs from the timing of invoicing, we have determined that our contracts generally do not include a significant financing component. The primary purpose of our invoicing terms is to provide customers with simple and predictable methods of purchasing our products and services, not to either provide or receive financing to or from our customers. We record contract liabilities when cash payments are received or due in advance of our performance.

We do not disclose the value of unsatisfied performance obligations for contracts with an original expected length of one year or less. Our payment terms vary by the type and location of our customer, and the products and services offered. The term between invoicing and when payment is due is not significant.

Reagent Rental Agreements

Reagent rental agreements are a diagnostic industry sales method that provides use of an instrument and consumables (reagents) to a customer on a per test basis. These agreements may also include maintenance of the underlying instruments retained at customer locations as well as initial training. We initially determine if a reagent rental arrangement contains a lease at lease commencement. Where we have determined that such an arrangement contains a lease, we next must ascertain its lease classification for purposes of applying appropriate accounting treatment as an operating, sales-type or direct financing lease. In addition, for purposes of determining the lease term used in performing the lease classification test, we include the noncancellable period of the lease together with those periods covered by the option to extend the lease if the customer is reasonably certain to exercise that option, the periods covered by an option to terminate the lease if the customer is reasonably certain not to exercise that option, and the periods covered by the option to extend (or not to terminate) the lease in which exercise of the option is controlled by the company. While most of our reagent rental arrangements contain either the option for a lessee to extend and/or cancel, the period in which the contract is enforceable is a very short period and therefore the lease term has been limited to the noncancellable period. Furthermore, it has historically been very rare for these arrangements to contain an option for the lessee to purchase the underlying asset.

As discussed further below under the captions “Leases” and “Recent Accounting Pronouncements Adopted,” as well as in Note 14, Leases, we adopted ASC 842, “Leases,” on a modified retrospective basis effective January 1, 2019 with practical expedients, and did not restate comparative prior periods. We concluded that the use of the instrument (referred to as “lease elements”) is not within the guidance of ASC 606 but rather ASC 842. Accordingly, we first allocate the transaction price between the lease elements and the non-lease elements based on relative standalone selling prices. The determination of the transaction price requires judgment and consideration of any fixed/minimum payments as well as estimates of variable consideration. After allocation, the amount of variable payments allocated to lease components will be recognized as income under ASC 842, while the amount of variable payments allocated to non-lease components will be recognized as income in accordance with ASC 606.

Upon our adoption of ASC 842 in 2019, the maintenance services, along with the reagents, are now allocated to the non-lease elements and will be recognized as income in accordance with ASC 606. This change is in alignment with the requirements of ASC 842, and has resulted in a decrease in the amount of rental income and a corresponding increase in the amount of maintenance service revenue that is included in total reported Net sales in our condensed consolidated income statements. Generally, the terms of the arrangements result in the transfer of control on reagents upon either (i) when the consumables are delivered or (ii) when the consumables are consumed by the customer.

Historically, our reagent rental arrangements have been predominantly comprised of variable lease payments that fluctuate depending on the volume of reagents purchased, as very few of such arrangements contain any fixed/minimum lease payments. As a result, our lease income is heavily variable in nature. Further, our reagent rental arrangements are predominantly classified as operating leases, and any sales-type leases represent in aggregate a very insignificant amount of lease income. Hence, our reported lease income is primarily variable in nature and is recognized as the reagents are consumed by the customer or delivered.

Revenue allocated to the lease elements of these reagent rental arrangements represents approximately 3% of total revenue for both the three and nine months ended September 30, 2019, and approximately 5% of total revenue for both the three and nine months ended September 30, 2018, and is included as part of Net sales in our Condensed Consolidated Statements of Income.

Contract costs:

As a practical expedient, we expense as incurred costs to obtain contracts as the amortization period would have been one year or less. These costs, recorded within Selling, general and administrative expense, include our internal sales force compensation programs and certain partner sales incentive programs, as we have determined that annual compensation is commensurate with annual selling activities.

Disaggregation of Revenue:

The following table presents our revenues disaggregated by geographic region based primarily on the location of the use of the product or service (in millions, unaudited):



	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2019		2018		2019		2018
Europe	$	181.9	$	182.7	$	556.1	$	579.5
Asia	120.7		110.3		354.3		341.7
United States	225.8		218.3		674.0		649.8
Other (primarily Canada and Latin America)	32.2		33.8		102.8		101.6
Total Net sales	$	560.6	$	545.1	$	1,687.2	$	1,672.6

The disaggregation of our revenue by industry segment sources is presented in our Segment Information footnote (see Note 11).

Deferred revenues represent mostly unrecognized fees billed or collected for extended service arrangements. Deferred revenues are generally recognized ratably over the term of the service contract as our performance extends over the life of the arrangement. A majority of our deferred revenue balance is classified as current with an expected length of one year or less. The increase in our total deferred revenue balance from $37.3 million at December 31, 2018 to $45.6 million at September 30, 2019 is primarily driven by $30.1 million, net, of cash payments received or due in advance of satisfying our performance obligations, partially offset by $21.8 million of revenue recognized that were included in our deferred revenue balance as of December 31, 2018.

We warrant certain equipment against defects in design, materials and workmanship, generally for a period of one year. Upon revenue recognition of that equipment, we establish, as part of Cost of goods sold, a provision for the expected costs of such warranty based on historical experience, specific warranty terms and customer feedback. A review is performed on a quarterly basis to assess the adequacy of our warranty accrual.

Components of the warranty accrual, included in Other current liabilities and Other long-term liabilities in the Condensed Consolidated Balance Sheets, were as follows (in millions):



December 31, 2018	$	10.1
Provision for warranty	7.3
Actual warranty costs	(8.4		)
September 30, 2019	$	9.0

Leases

We determine if an arrangement is a lease at inception. Operating leases are included in Operating lease right-of-use (“ROU”) assets, Current operating lease liabilities, and Operating lease liabilities in our Condensed Consolidated Balance Sheet as of September 30, 2019. Finance leases are included in Property, plant and equipment, Current maturities of long-term debt and notes payable, and Long-term debt, net of current maturities in our Condensed Consolidated Balance Sheet as of September 30, 2019.

ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. Where we act as lessee, we elected not to separate lease and non-lease components.

Where we act as lessor in our reagent rental arrangements, we allocate the consideration in the contract to the separate lease components and non-lease components. After allocation, the amount of variable payments allocated to lease components will be recognized as income under the lease accounting standard ASC 842, while the amount of variable payments allocated to non-lease components will be recognized as income in accordance with ASC 606. Such reagent rental arrangements are more fully described above under the caption "Reagent Rental Agreements."

Recent Accounting Pronouncements and Securities and Exchange Commission ("SEC") Rule Adopted

In August 2018, the FASB issued ASU 2018-15, "Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract." ASU 2018-15 amends the definition of a hosting arrangement and requires a customer in a hosting arrangement that is a service contract to capitalize certain implementation costs as if the arrangement was an internal-use software project. The internal-use software guidance states that only qualifying costs incurred during the application development stage can be capitalized. We prospectively adopted ASU 2018-15 effective January 1, 2019. As of September 30, 2019, we capitalized $2.4 million of implementation costs for cloud computing arrangements, net of accumulated amortization, primarily for business analytics software. These costs were recorded in Other current assets and Other assets in the Condensed Consolidated Balance Sheet.

In August 2018, the SEC issued Final Rule Release No. 33-10532, "Disclosure Update and Simplification" that extends to interim periods the annual disclosure requirement of presenting the changes in stockholders' equity, which was effective in the first quarter of 2019.

In February 2016, the FASB issued ASU 2016-02, "Leases," and related accounting standard updates, which requires, among other items, lease accounting to recognize most leases as assets and liabilities on the balance sheet. Qualitative and quantitative disclosures are enhanced to better understand the amount, timing and uncertainty of cash flows arising from leases. We adopted ASU 2016-02 on a modified retrospective basis effective January 1, 2019 with practical expedients, and did not restate comparative prior periods. The practical expedients elected in transition included, among other items, for leases that existed prior to January 1, 2019, not reassessing whether any contracts are or contain embedded leases, not reassessing the classification of existing leases, and not reassessing whether previously capitalized initial direct costs qualify for capitalization. Where we act as a lessee, the adoption of the standard resulted in material additions to the balance sheet for right-of-use assets and the associated liabilities, see Note 14, Leases. Where we act as a lessee, we also elected not to separate lease and non-lease components. Where we act as a lessor in reagent rental arrangements, there was an insignificant impact to our Condensed Consolidated Financial Statements, which is more fully described above under the caption "Reagent Rental Agreements."

Recent Accounting Pronouncements to be Adopted

In November 2018, the FASB issued ASU 2018-18, "Clarifying the Interaction between Topic 808 and Topic 606." Topic 808 is Collaborative Arrangements, and Topic 606 is Revenue from Contracts with Customers. ASU 2018-18 clarifies that certain transactions between collaborative partners should be accounted for as revenue under ASC 606 when the collaborative partner is a customer. We currently do not have any customers that are collaborative partners or anticipate any in the near future. ASU 2018-18 will be effective January 1, 2020.

In August 2018, the FASB issued ASU 2018-14, "Disclosure Framework - Changes to the Disclosure Requirements for Defined Benefit Plans." ASU 2018-14 eliminates and adds certain disclosures for defined benefit plans. ASU 2018-14 is effective for fiscal years ending after December 15, 2020 using a retrospective approach. We are currently evaluating the disclosures but do not expect ASU 2018-14 to have a material impact to our disclosures for defined benefit plans.

In August 2018, the FASB issued ASU 2018-13, "Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement." ASU 2018-13 eliminates, adds and modifies certain disclosures for fair value measurements. ASU 2018-13 is effective for fiscal years beginning after December 15, 2019 and for interim periods within those fiscal years. We do not expect ASU 2018-13 to have a material impact to our fair value disclosures.

In June 2016, the FASB issued ASU 2016-13, "Measurement of Credit Losses on Financial Instruments." ASU 2016-13 will replace the current incurred loss approach with an expected loss model for instruments measured at amortized cost and require entities to record allowances for available-for-sale debt securities rather than reduce the carrying amount under the current other-than-temporary impairment model. ASU 2016-13 is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. We are currently evaluating the effect ASU 2016-13 will have on our consolidated financial statements.

2.ACQUISITIONS

In August 2019, we acquired all the issued and outstanding membership interests of a small U.S. manufacturer for approximately $60.0 million. Cash payments at closing, net of closing cash, were $59.7 million. The acquisition was included in our Clinical Diagnostics segment's results of operations from the acquisition date and was accounted for as a business combination. The amount of acquisition-related costs was minimal as Bio-Rad primarily represented itself during the acquisition process. The goodwill related to this acquisition is deductible for income tax purposes. Proforma financial statements are not provided as the acquisition is immaterial to Bio-Rad taken as a whole for the periods presented.

As of September 30, 2019, the preliminary allocation of the payments were $26.8 million to purchased intangibles consisting primarily of customer relationships, developed product technology and tradenames, $4.2 million to acquired net assets, and $28.7 million to goodwill. The purchase price allocation is preliminary as additional time is required to complete the valuation of assets acquired and liabilities assumed.

We believe that the acquisition will accelerate market penetration in the areas of quality controls and assay verification panels in our Clinical Diagnostics operations.

In March 2019, we completed the acquisition of all the issued and outstanding stock of a small U.S. private company for approximately $20.0 million. Cash payments, net of closing cash, consisted of $4.0 million paid in November 2018 and the remaining $16.0 million paid in March 2019. The acquisition was included in our Life Science segment's results of operations from the acquisition date and was accounted for as a business combination. The amount of acquisition-related costs was minimal as Bio-Rad primarily represented itself during the acquisition process. The goodwill related to this acquisition is not deductible for income tax purposes. Pro forma financial statements are not provided as the acquisition is immaterial to Bio-Rad taken as a whole for the periods presented.

The final allocation of the payments were $15.6 million to goodwill that included workforce and time-to-market advantage, $5.5 million to definite-lived intangibles, $0.2 million to in-process research and development, an indefinite-lived intangible asset, and a deferred tax liability of $1.3 million related to the purchased intangibles.

We believe that the acquisition will expand our reagents suite of offerings in our Life Science operations.

3.FAIR VALUE MEASUREMENTS

We determine the fair value of an asset or liability based on the assumptions that market participants would use in pricing the asset or liability in an orderly transaction between market participants at the measurement date. The identification of market participant assumptions provides a basis for determining what inputs are to be used for pricing each asset or liability. A fair value hierarchy has been established which gives precedence to fair value measurements calculated using observable inputs over those using unobservable inputs. This hierarchy prioritizes the inputs into three broad levels as follows:


•	Level 1: Quoted prices in active markets for identical instruments


•	Level 2: Other significant observable inputs (including quoted prices in active markets for similar instruments)


•	Level 3: Significant unobservable inputs (including assumptions in determining the fair value of certain investments)

Financial assets and liabilities carried at fair value and measured on a recurring basis as of September 30, 2019 are classified in the hierarchy as follows (in millions):



	Level 1		Level 2		Level 3		Total
Financial assets carried at fair value:
Cash equivalents:
Commercial paper	$	—	$	76.6	$	—	$	76.6
Asset-backed securities	—		0.1		—		0.1
U.S. government sponsored agencies	—		3.2		—		3.2
Time deposits	23.6		10.0		—		33.6
Money market funds	62.9		—		—		62.9
Total cash equivalents (a)	86.5		89.9		—		176.4
Restricted investment	5.6		—		—		5.6
Equity securities (b)	3,950.5		—		—		3,950.5
Available-for-sale investments:
Corporate debt securities	—		181.7		—		181.7
U.S. government sponsored agencies	—		98.5		—		98.5
Foreign government obligations	—		4.7		—		4.7
Other foreign obligations	—		3.1		—		3.1
Municipal obligations	—		10.7		—		10.7
Asset-backed securities	—		72.2		—		72.2
Total available-for-sale investments (c)	—		370.9		—		370.9
Forward foreign exchange contracts (d)	—		0.5		—		0.5
Total financial assets carried at fair value	$	4,042.6	$	461.3	$	—	$	4,503.9

Financial liabilities carried at fair value:
Forward foreign exchange contracts (e)	$	—	$	0.8	$	—	$	0.8
Contingent consideration (f)	—		—		5.3		5.3
Total financial liabilities carried at fair value	$	—	$	0.8	$	5.3	$	6.1

Financial assets and liabilities carried at fair value and measured on a recurring basis as of December 31, 2018 are classified in the hierarchy as follows (in millions):



	Level 1		Level 2		Level 3		Total
Financial assets carried at fair value:
Cash equivalents:
Commercial paper	$	—	$	77.8	$	—	$	77.8
Time deposits	22.7		10.0		—		32.7
Asset-backed securities	—		0.3		—		0.3
Money market funds	36.9		—		—		36.9
Total cash equivalents (a)	59.6		88.1		—		147.7
Restricted investment	5.6		—		—		5.6
Equity securities (b)	2,672.9		—		—		2,672.9
Available-for-sale investments:
Corporate debt securities	—		215.0		—		215.0
U.S. government sponsored agencies	—		80.3		—		80.3
Foreign government obligations	—		3.6		—		3.6
Municipal obligations	—		11.0		—		11.0
Asset-backed securities	—		63.3		—		63.3
Total available-for-sale investments (c)	—		373.2		—		373.2
Forward foreign exchange contracts (d)	—		0.6		—		0.6
Total financial assets carried at fair value	$	2,738.1	$	461.9	$	—	$	3,200.0

Financial liabilities carried at fair value:
Forward foreign exchange contracts (e)	$	—	$	0.7	$	—	$	0.7
Contingent consideration (f)	—		—		8.4		8.4
Total financial liabilities carried at fair value	$	—	$	0.7	$	8.4	$	9.1


(a)	Cash equivalents are included in Cash and cash equivalents in the Condensed Consolidated Balance Sheets.


(b)	Equity securities are included in the following accounts in the Condensed Consolidated Balance Sheets (in millions):



	September 30, 2019		December 31, 2018
Short-term investments	$	47.4	$	40.2
Other investments	3,903.1		2,632.7
Total	$	3,950.5	$	2,672.9

The year-to-date unrealized gains on our equity securities as of September 30, 2019 were $1,385.0 million and were primarily due to our investment in Sartorius AG and are recorded in our Condensed Consolidated Statements of Income.


(c)	Available-for-sale investments are included in the following accounts in the Condensed Consolidated Balance Sheets (in millions):



	September 30, 2019		December 31, 2018
Short-term investments	$	370.8	$	373.0
Other investments	0.1		0.2
Total	$	370.9	$	373.2

(d) Forward foreign exchange contracts in an asset position are included in Other current assets in the Condensed Consolidated Balance Sheets.

(e) Forward foreign exchange contracts in a liability position are included in Other current liabilities in the Condensed Consolidated Balance Sheets.

(f) Contingent consideration liability is included in the following accounts in the Condensed Consolidated Balance Sheets (in millions):



	September 30, 2019		December 31, 2018
Other current liabilities	$	3.7	$	3.2
Other long-term liabilities	1.6		5.2
Total	$	5.3	$	8.4

During the first quarter of 2016, we recognized a contingent consideration liability upon our acquisition of a high performance analytical flow cytometer platform from Propel Labs. At the acquisition date, the amount of contingent consideration was determined based on a probability-weighted income approach related to the achievement of sales milestones, ranging from 39% to 20% for the calendar years 2017 through 2020. The sales milestones could potentially range from $0 to an unlimited amount. In the first and third quarters of 2019, we paid $1.4 million and $1.1 million, respectively, per the purchase agreement. Since 2016 we have decreased the cumulative valuation of the sales milestones by net $12.9 million. The contingent consideration was accrued at its estimated fair value of $5.3 million as of September 30, 2019.

The following table provides a reconciliation of the Level 3 analytical flow cytometer platform contingent consideration liabilities measured at estimated fair value (in millions):



December 31, 2018	$	8.4
Payment of sales milestone	(2.5		)
Decrease in estimated fair value of contingent consideration included in Selling, general and administrative expense	(0.6		)
September 30, 2019	$	5.3

The following table provides quantitative information about Level 3 inputs for fair value measurement of our analytical flow cytometer platform contingent consideration liability as of September 30, 2019. Significant increases or decreases in these inputs in isolation could result in a significantly lower or higher fair value measurement.




	Valuation Technique	Unobservable Input
Analytical flow cytometer platform	Probability-weighted income approach	Sales milestones:
		Discount rate	11.4	%
		Average cost of debt	3.9	%

To estimate the fair value of Level 2 debt securities as of September 30, 2019, our primary pricing provider uses Reuters as the primary pricing source. Our pricing process allows us to select a hierarchy of pricing sources for securities held. If Reuters does not price a Level 2 security that we hold, then the pricing provider will utilize our custodian supplied pricing as the secondary pricing source.

For all commercial paper as of September 30, 2019, our primary pricing provider uses its leading pricing source in the hierarchy to determine pricing.

Our pricing provider performs daily reasonableness testing of the Reuters prices. Price changes of 5% or greater are investigated and resolved. In addition, we perform a quarterly testing of the Reuters prices to custodian reported prices. Price differences outside a tolerable variance of approximately 1% are investigated and resolved.

Available-for-sale investments consist of the following (in millions):



	September 30, 2019
	Amortized Cost		Unrealized Gains		Unrealized Losses			Estimated Fair Value
Short-term investments:
Corporate debt securities	$	180.3	$	1.5	$	(0.1	)	$	181.7
Municipal obligations	10.6		0.1		—			10.7
Asset-backed securities	72.0		0.2		(0.1		)	72.1
U.S. government sponsored agencies	97.6		1.0		(0.1		)	98.5
Foreign government obligations	4.7		—		—			4.7
Other foreign obligations	3.1		—		—			3.1
	368.3		2.8		(0.3		)	370.8
Long-term investments:
Asset-backed securities	0.1		—		—			0.1
	0.1		—		—			0.1
Total	$	368.4	$	2.8	$	(0.3	)	$	370.9

The following is a summary of the amortized cost and estimated fair value of our debt securities at September 30, 2019 by contractual maturity date (in millions):



	Amortized Cost		Estimated Fair Value
Mature in less than one year	$	139.9	$	140.0
Mature in one to five years	168.3		169.4
Mature in more than five years	60.2		61.5
Total	$	368.4	$	370.9

Available-for-sale investments consist of the following (in millions):



	December 31, 2018
	Amortized Cost		Unrealized Gains		Unrealized Losses			Estimated Fair Value
Short-term investments:
Corporate debt securities	$	216.2	$	0.1	$	(1.3	)	$	215.0
Municipal obligations	11.1		—		(0.1		)	11.0
Asset-backed securities	63.5		—		(0.4		)	63.1
U.S. government sponsored agencies	80.9		0.2		(0.8		)	80.3
Foreign government obligations	3.6		—		—			3.6
	375.3		0.3		(2.6		)	373.0
Long-term investments:
Asset-backed securities	0.2		—		—			0.2
	0.2		—		—			0.2
Total	$	375.5	$	0.3	$	(2.6	)	$	373.2

The following is a summary of investments with gross unrealized losses and the associated fair value (in millions):



	September 30, 2019		December 31, 2018
Fair value of investments in a loss position 12 months or more	$	27.3	$	117.9
Fair value of investments in a loss position less than 12 months	$	90.3	$	193.0
Gross unrealized losses for investments in a loss position 12 months or more	$	0.1	$	1.8
Gross unrealized losses for investments in a loss position less than 12 months	$	0.2	$	0.8

The unrealized losses on these securities are due to a number of factors, including changes in interest rates, changes in economic conditions and changes in market outlook for various industries, among others. Because Bio-Rad has the ability and intent to hold these investments with unrealized losses until a recovery of fair value, or for a reasonable period of time sufficient for a forecasted recovery of fair value, which may be maturity, we do not consider these investments to be other-than-temporarily impaired at September 30, 2019 or at December 31, 2018.

As part of distributing our products, we regularly enter into intercompany transactions. We enter into forward foreign exchange contracts to manage foreign exchange risk of future movements in foreign exchange rates that affect foreign currency denominated intercompany receivables and payables. We do not use derivative financial instruments for speculative or trading purposes. We do not seek hedge accounting treatment for these contracts. As a result, these contracts, generally with maturity dates of 90 days or less and denominated primarily in currencies of industrial countries, are recorded at their fair value at each balance sheet date. The notional principal amounts provide one measure of the transaction volume outstanding as of September 30, 2019 and do not represent the amount of Bio-Rad's exposure to loss. The estimated fair value of these contracts was derived using the spot rates from Reuters on the last business day of the quarter and the points provided by counterparties. The resulting gains or losses offset exchange gains or losses on the related receivables and payables, both of which are included in Foreign currency exchange losses, net in the Condensed Consolidated Statements of Income.

The following is a summary of our forward foreign exchange contracts (in millions):



	September 30,
	2019
Contracts maturing in October through December 2019 to sell foreign currency:
Notional value	$	37.6
Unrealized gain or loss	$	—
Contracts maturing in October through December 2019 to purchase foreign currency:
Notional value	$	232.5
Unrealized loss	$	0.2

The estimated fair value of our long-term debt, excluding all leases and current maturities, that is not recognized at fair value in the Condensed Consolidated Balance Sheets has an estimated fair value based on quoted market prices for the same or similar issues.

The estimated fair value of our long-term debt discussed above and the level of the fair value hierarchy within which the fair value measurement is categorized are as follows (in millions):



	September 30, 2019					December 31, 2018
	Carrying Amount		Estimated Fair Value		Fair Value Hierarchy Level	Carrying Amount		Estimated Fair Value		Fair Value Hierarchy Level
Total long-term debt, excluding leases and current maturities	$	424.2	$	435.1	2	$	423.7	$	435.8	2

Included in Other Investments in the Condensed Consolidated Balance Sheet are investments without readily determinable fair value measured at cost with adjustments for observable price changes in price or impairments. The carrying value of these investments was $3.6 million and $0.6 million as of September 30, 2019 and December 31, 2018, respectively.

4.GOODWILL AND OTHER PURCHASED INTANGIBLE ASSETS

Changes to goodwill by segment were as follows (in millions):



	Life Science			Clinical Diagnostics			Total
Balances as of December 31, 2018:
Goodwill	$	234.5		$	320.5		$	555.0
Accumulated impairment losses	(41.8		)	(293.4		)	(335.2		)
Goodwill, net	192.7			27.1			219.8

Acquisitions	15.6			28.7			44.3

Balances as of September 30, 2019:
Goodwill	250.1			349.2			599.3
Accumulated impairment losses	(41.8		)	(293.4		)	(335.2		)
Goodwill, net	$	208.3		$	55.8		$	264.1

In conjunction with the purchase of all the issued and outstanding membership interest of a small U.S. manufacturer in August 2019 (see Note 2, "Acquisitions"), we recorded $28.7 million of goodwill and $26.8 million of definite-lived intangible assets: $16.1 million of Customer relationships, $8.1 million of Developed product technology, $2.5 million of Tradenames and $0.1 million of Backlog.

In conjunction with the purchase of all the issued and outstanding stock of a small U.S. private company in March 2019 (see Note 2, "Acquisitions"), we recorded $15.6 million of goodwill that included workforce and time-to-market advantage, $5.5 million of Developed product technology, a definite-lived intangible asset, and $0.2 million of In-process research and development, an indefinite-lived intangible asset.

Information regarding our identifiable purchased intangible assets with definite and indefinite lives is as follows (in millions):



	September 30, 2019
	Average Remaining Life (years)	Purchase Price		Accumulated Amortization			Net Carrying Amount
Customer relationships/lists	1-10	$	101.4	$	(70.4	)	$	31.0
Know how	1-6	186.0		(158.9		)	27.1
Developed product technology	1-13	141.5		(90.1		)	51.4
Licenses	6-10	75.7		(43.3		)	32.4
Tradenames	2-10	6.4		(3.5		)	2.9
Covenants not to compete	6	3.2		(1.3		)	1.9
Other	1	0.1		—			0.1
Total definite-lived intangible assets		514.3		(367.5		)	146.8
In-process research and development		0.2		—			0.2
Total purchased intangible assets		$	514.5	$	(367.5	)	$	147.0



	December 31, 2018
	Average Remaining Life (years)	Purchase Price		Accumulated Amortization			Net Carrying Amount
Customer relationships/lists	1-6	$	88.7	$	(68.3	)	$	20.4
Know how	1-7	190.6		(159.8		)	30.8
Developed product technology	1-10	130.4		(86.6		)	43.8
Licenses	7-11	76.3		(40.9		)	35.4
Tradenames	2-6	3.9		(3.3		)	0.6
Covenants not to compete	7	3.2		(1.1		)	2.1
Total definite-lived intangible assets		$	493.1	$	(360.0	)	$	133.1

Amortization expense related to purchased intangible assets is as follows (in millions):



	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2019		2018		2019		2018

Amortization expense	$	6.0	$	7.0	$	17.1	$	21.8

5. SUPPLEMENTAL CASH FLOW INFORMATION

The reconciliation of net income to net cash provided by operating activities is as follows (in millions):



	Nine Months Ended
	September 30, 2019			September 30, 2018
Net income	$	1,205.2		$	1,194.1
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	99.8			103.6
Right-of-use asset amortization	31.1			—
Share-based compensation	25.4			19.2
(Gains) losses on dispositions of securities	(0.2		)	1.0
Other-than-temporary impairment loss on investment	1.6			—
Change in fair market value of equity securities	(1,385.0		)	(1,420.3		)
Gain on divestiture of a product line	—			(5.1		)
Losses on dispositions of fixed assets	0.3			1.2
Gain on sale of land	—			(4.1		)
Changes in fair value of contingent consideration	(0.6		)	(6.5		)
Payments for operating lease liabilities	(27.6		)	—
Decrease in accounts receivable	30.4			72.2
Increase in inventories	(14.5		)	(26.3		)
Decrease (increase) in other current assets	47.9			(8.9		)
Decrease in accounts payable and other current liabilities	(24.6		)	(43.1		)
Decrease in income taxes payable	(2.8		)	(22.1		)
Increase in deferred income taxes	310.9			316.7
Increase in other long term liabilities	5.5			5.4
Other	(4.7		)	3.5
Net cash provided by operating activities	$	298.1		$	180.5

Non-cash investing activities:
Purchased property, plant and equipment	$	4.5		$	5.7
Purchased marketable securities and investments	$	2.8		$	1.2

6. LONG-TERM DEBT

The principal components of long-term debt are as follows (in millions):



	September 30, 2019			December 31, 2018
4.875% Senior Notes due 2020 principal amount	$	425.0		$	425.0
Less unamortized discount and debt issuance costs	(0.8		)	(1.3		)
4.875% Senior Notes less unamortized discount and debt issuance costs	424.2			423.7
Capital leases and other debt	—			15.7
Finance leases and other debt	15.4			—
	439.6			439.4
Less current maturities	(1.8		)	(0.5		)
Long-term debt	$	437.8		$	438.9

Senior Notes due 2020

In December 2010, Bio-Rad sold $425.0 million principal amount of Senior Notes due December 2020 (4.875% Notes). The sale yielded net cash proceeds of $422.6 million at an effective rate of 4.946%. The 4.875% Notes pay a fixed rate of interest of 4.875% per year. We have the option to redeem any or all of the 4.875% Notes at any time at a redemption price of 100% of the principal amount (plus a specified make-whole premium as defined in the indenture governing the 4.875% Notes) and accrued and unpaid interest thereon to the redemption date. Our obligations under the 4.875% Notes are not secured and rank equal in right of payment with all of our existing and future unsubordinated indebtedness. Certain covenants apply at each year end to the 4.875% Notes including limitations on the following: liens, sale and leaseback transactions, mergers, consolidations or sales of assets and other covenants. We were in compliance with these covenants as of September 30, 2019. There are no restrictive covenants relating to total indebtedness, interest coverage, stock repurchases, recapitalizations, dividends and distributions to shareholders or current ratios.

Credit Agreement

In April 2019, Bio-Rad entered into a $200 million unsecured Credit Agreement. Borrowings under the 2019 Credit Agreement are on a revolving basis and can be used to make permitted acquisitions, for working capital and for other general corporate purposes. We had no outstanding borrowings under the 2019 Credit Agreement as of September 30, 2019, however, $0.2 million was utilized for domestic standby letters of credit that reduced our borrowing availability as of September 30, 2019. The 2019 Credit Agreement matures in April 2024. If we had borrowed against our 2019 Credit Agreement, the borrowing rate would have been 3.225% at September 30, 2019, which is based on the 3-month LIBOR.

The 2019 Credit Agreement requires Bio-Rad to comply with certain financial ratios and covenants, among other things. These ratios and covenants include a leverage ratio test and an interest coverage test, as well as restrictions on our ability to declare or pay dividends, incur debt, guarantee debt, enter into transactions with affiliates, merge or consolidate, sell assets, make investments and create liens. We were in compliance with all of these ratios and covenants as of September 30, 2019.

7. ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)

Accumulated other comprehensive income included in our Condensed Consolidated Balance Sheets consists of the following components (in millions):



	Foreign currency translation adjustments			Foreign other post-employment benefits adjustments			Net unrealized holding gains on available-for-sale investments			Total accumulated other comprehensive income (loss)
Balances as of January 1, 2019:	$	(35.5	)	$	(14.8	)	$	3.3		$	(47.0	)
Other comprehensive (loss) income, before reclassifications	(109.9		)	0.1			5.1			(104.7		)
Amounts reclassified from Accumulated other comprehensive income	—			0.6			(0.3		)	0.3
Income tax effects	—			(0.2		)	(0.6		)	(0.8		)
Other comprehensive (loss) income, net of income taxes	(109.9		)	0.5			4.2			(105.2		)
Balances as of September 30, 2019:	$	(145.4	)	$	(14.3	)	$	7.5		$	(152.2	)



	Foreign currency translation adjustments			Foreign other post-employment benefits adjustments			Net unrealized holding gains on available-for-sale investments			Total accumulated other comprehensive income (loss)
Balances as of January 1, 2018:	$	77.4		$	(22.3	)	$	4.5		$	59.6
Other comprehensive (loss) income, before reclassifications	(91.2		)	0.5			(2.3		)	(93.0		)
Amounts reclassified from Accumulated other comprehensive income	—			1.2			0.3			1.5
Income tax effects	—			(0.4		)	—			(0.4		)
Other comprehensive (loss) income, net of income taxes	(91.2		)	1.3			(2.0		)	(91.9		)
Balances as of September 30, 2018:	$	(13.8	)	$	(21.0	)	$	2.5		$	(32.3	)

The amounts reclassified out of Accumulated other comprehensive income into the Condensed Consolidated Statements of Income, with presentation location, were as follows:



	Income before taxes impact (in millions):
		Three Months Ended						Nine Months Ended
		September 30,						September 30,
Components of Comprehensive income		2019			2018			2019			2018			Location
Amortization of foreign other post-employment benefit items		$	(0.2	)	$	(0.4	)	$	(0.6	)	$	(1.2	)	Other (income) expense, net
Net holding gains (losses) on equity securities and available-for-sale investments		$	0.2		$	(0.1	)	$	0.3		$	(0.3	)	Other (income) expense, net

Reclassification adjustments are calculated using the specific identification method.

8. EARNINGS (LOSS) PER SHARE

Basic earnings (loss) per share is computed by dividing net income attributable to Bio-Rad by the weighted average number of common shares outstanding for that period. Diluted earnings (loss) per share takes into account the effect of dilutive instruments, such as stock options and restricted stock, and uses the average share price for the period in determining the number of potential common shares that are to be added to the weighted average number of shares outstanding. Potential common shares are excluded from the diluted earnings (loss) per share calculation if the effect of including such securities would be anti-dilutive. For the three months ended September 30, 2019, net loss per basic share was the same as net loss per diluted share because all potentially dilutive shares were anti-dilutive due to the net loss for the period.

The weighted average number of common shares outstanding used to calculate basic and diluted earnings per share, and the anti-dilutive shares that are excluded from the diluted earnings per share calculation are as follows (in thousands):



	Three Months Ended		Nine Months Ended
	September 30,		September 30,
	2019	2018	2019	2018
Basic weighted average shares outstanding	29,831	29,863	29,815	29,822
Effect of potentially dilutive stock options and restricted stock awards	—	429	334	412
Diluted weighted average common shares	29,831	30,292	30,149	30,234
Anti-dilutive shares	95	64	56	35

9. OTHER INCOME AND EXPENSE, NET

Other (income) expense, net includes the following components (in millions):



	Three Months Ended						Nine Months Ended
	September 30,						September 30,
	2019			2018			2019			2018
Interest and investment income	$	(4.1	)	$	(2.6	)	$	(27.4	)	$	(20.9	)
Net realized (gain) loss on investments	(0.2		)	0.1			(0.2		)	0.3
Other-than-temporary impairment loss on investment	—			—			1.6			—
Gain on sale of land	—			—			—			(4.1		)
Gain on divestiture of product line	—			—			—			(5.1		)
Other (income) expense	(0.1		)	(0.1		)	(1.0		)	0.2
Other (income) expense, net	$	(4.4	)	$	(2.6	)	$	(27.0	)	$	(29.6	)

An other-than-temporary impairment loss on investment was recorded in light of the investee's financial condition in the first quarter of 2019.

10. INCOME TAXES

Our effective income tax rate was 23% for both the three and nine months ended September 30, 2019 and 2018.

The realization of deferred tax assets is dependent upon the generation of sufficient taxable income of the appropriate character in future periods. We regularly assess our ability to realize our deferred tax assets and establish a valuation allowance if it is more likely than not that some portion, or all, of our deferred tax assets will not be realized. In assessing the realizability of our deferred tax assets, we weigh all available positive and negative evidence. Due to the weight of objectively verifiable negative evidence, we believe that it is more likely than not that our California and certain foreign deferred tax assets will not be realized as of September 30, 2019, and have maintained a valuation allowance on such deferred tax assets.

We record liabilities for unrecognized tax benefits related to uncertain tax positions. We do not believe any currently pending uncertain tax positions will have a material adverse effect on our condensed consolidated financial statements, although an adverse resolution of one or more of these uncertain tax positions in any period may have a material impact on the results of operations for that period.

As of September 30, 2019, based on the expected outcome of certain examinations or as a result of the expiration of statute of limitations for certain jurisdictions, we believe that within the next 12 months it is reasonably possible that our previously unrecognized tax benefits could decrease by up to $2.1 million.

11. SEGMENT INFORMATION

Information regarding industry segments for the three months ended September 30, 2019 and 2018 is as follows (in millions):



		Life Science		Clinical Diagnostics		Other Operations

Segment net sales	2019	$	215.7	$	341.8	$	3.1
	2018	$	206.6	$	334.0	$	4.5

Segment net profit (loss)	2019	$	11.6	$	43.8	$	(0.4	)
	2018	$	10.2	$	22.4	$	0.1

Information regarding industry segments for the nine months ended September 30, 2019 and 2018 is as follows (in millions):



		Life Science		Clinical Diagnostics		Other Operations

Segment net sales	2019	$	643.9	$	1,032.9	$	10.4
	2018	$	622.2	$	1,038.8	$	11.6

Segment net profit (loss)	2019	$	45.9	$	117.1	$	(1.1	)
	2018	$	25.7	$	86.8	$	0.1

Information regarding industry segments at September 30, 2019, and December 31, 2018 is as follows (in millions):



		Life Science		Clinical Diagnostics		Other Operations

Segment assets	September 30, 2019	$	500.0	$	1,085.6	$	7.8
	December 31, 2018	$	450.2	$	949.0	$	5.9

Segment results are presented in the same manner as we present our operations internally to make operating decisions and assess performance. Net corporate operating, interest and other expense for segment results consists of receipts and expenditures that are not the primary responsibility of segment operating management and therefore are not allocated to the segments for performance assessment by our chief operating decision maker. Interest expense is charged to segments based on the carrying amount of inventory and receivables employed by that segment. For the three months ended September 30, 2019 compared to the same period in 2018, our Life Science segment had increased sales, partially offset by increased cost of goods sold and selling, general and administrative expense, while our Clinical Diagnostics segment had increased sales, decreased cost of goods sold, along with decreased selling, general and administrative expense. For the nine months ended September 30, 2019 compared to the same period in 2018, our Life Science segment had increased sales and decreased cost of goods sold, partially offset by increased research and development expense, while our Clinical Diagnostics segment had decreased sales, offset by decreased cost of goods sold, selling, general and administrative and research and development expenses. Segment assets at September 30, 2019 increased from December 31, 2018 balances due to inclusion of operating lease right-of-use assets in segment assets (see Note 14, "Leases"). The following reconciles total segment profit to consolidated (loss) income before income taxes (in millions):



	Three Months Ended						Nine Months Ended
	September 30,						September 30,
	2019			2018			2019			2018
Total segment profit	$	55.0		$	32.7		$	161.9		$	112.6
Foreign currency exchange losses, net	(0.9		)	(0.7		)	(3.4		)	(1.9		)
Net corporate operating, interest and other expense not allocated to segments	(3.1		)	(2.5		)	(8.8		)	(6.7		)
Change in fair market value of equity securities	(390.6		)	318.0			1,385.0			1,420.3
Other income (expense), net	4.4			2.6			27.0			29.6
Consolidated (loss) income before income taxes	$	(335.2	)	$	350.1		$	1,561.7		$	1,553.9

The following reconciles total segment assets to consolidated total assets (in millions):



	September 30, 2019		December 31, 2018
Total segment assets	$	1,593.4	$	1,405.1
Cash and other current assets	1,103.6		1,047.2
Property, plant and equipment, net, excluding
segment specific gross machinery and equipment	64.0		79.9
Goodwill, net	264.1		219.8
Other long-term assets	4,152.0		2,859.1
Total assets	$	7,177.1	$	5,611.1

12. LEGAL PROCEEDINGS

On May 27, 2015, our former general counsel, Sanford S. Wadler, filed a lawsuit in the U.S. District Court, Northern District of California, against us and four of our then current directors and one former director. The plaintiff’s suit alleged whistleblower retaliation in violation of the Sarbanes-Oxley Act and the Dodd-Frank Act for raising FCPA-related concerns. Mr. Wadler also alleged wrongful termination in violation of public policy, non-payment of wages and waiting time penalties in violation of the California Labor Code. The plaintiff sought back pay, compensatory damages for lost wages, earnings, retirement benefits and other employee benefits, compensation for mental pain and anguish and emotional distress, waiting time penalties, punitive damages, litigation costs (including attorneys’ fees) and reinstatement of employment. On July 28, 2015 we filed a motion to dismiss the plaintiff's complaint and specifically requested dismissal of the claims alleged against us under the Dodd-Frank Act and California Labor Code 1102.5 and the claims against the directors under the Sarbanes-Oxley Act and the Dodd-Frank Act. On October 23, 2015, the District Court granted our motion with respect to the alleged violations of the Sarbanes-Oxley Act against all the director defendants except Norman Schwartz with prejudice. The Court denied our motion to dismiss the claims under the Dodd-Frank Act as against both us and the director defendants. The trial commenced on January 17, 2017 and concluded on February 6, 2017. Mr. Wadler was awarded $10.92 million, plus prejudgment interest of $141,608, post-judgment interest, and Mr. Wadler’s litigation costs, expert witness fees, and reasonable attorneys’ fees as approved by the Court. We previously accrued for the judgment, interest and Mr. Wadler's litigation costs. On June 6, 2017, we filed a notice of appeal with the United States Court of Appeals for the Ninth Circuit. Oral arguments occurred on November 14, 2018. On February 26, 2019, the United States Court of Appeals for the Ninth Circuit issued its decision, reversing in part, vacating in part, and affirming in part. Specifically, the court: (1) reversed the Dodd-Frank claim, which amounts to about $2.96 million plus interest, and directed the district court to enter judgment in Bio-Rad’s favor on that claim; (2) vacated the SOX claim due to instructional error and remanded for further proceedings, including whether a new trial is needed; and (3) affirmed the California public policy claim and the $7.96 million in damages attributable to it. On March 12, 2019 we filed a petition for panel rehearing or rehearing en banc with the United States Court of Appeals for the Ninth Circuit, and this petition was denied on April 8, 2019. On September 24, 2019, Mr. Wadler filed a dismissal with prejudice of all remaining claims under the lawsuit with the U.S. District Court, Northern District of California as a result of a Confidential Settlement Agreement and Satisfaction of Judgment that the parties entered into that was last executed on September 6, 2019. This matter did not have a material impact on the third quarter 2019 results of operations and is now closed.

We are also party to various other claims, legal actions and complaints arising in the ordinary course of business. We cannot at this time reasonably estimate a range of exposure, if any, of the potential liability with respect to these matters. While we do not believe, at this time, that any ultimate liability resulting from any of these other matters will have a material adverse effect on our results of operations, financial position or liquidity, we cannot give any assurance regarding the ultimate outcome of these other matters and their resolution could be material to our operating results for any particular period, depending on the level of income for the period.

13. RESTRUCTURING COSTS

Restructuring Costs for European Reorganization

In May, 2016, we announced that we would take certain actions in our Europe geographic region designed to better align expenses to our revenue and gross margin profile and position us for improved operating performance. These actions, aligned with the creation and evolution of our organization structure and coordinated with the implementation of our global single instance enterprise resource planning ("ERP") platform, are expected to be incurred through 2019. We recorded less than $0.1 million and $(0.1) million of adjustments in restructuring charges related to severance and other employee benefits for the three and nine months ended September 30, 2019, respectively. The amounts recorded were reflected in Cost of goods sold of $(0.1) million in the Condensed Consolidated Statements of Income for the nine months ended September 30, 2019. From May 2016 to September 30, 2019, total expenses were $12.7 million. The liability of $0.7 million as of September 30, 2019 was recorded in Accrued payroll and employee benefits in the Condensed Consolidated Balance Sheets, and is expected to be paid or adjusted by the end of 2019.

Restructuring Costs for Termination of a Diagnostics Research and Development Project and Facility Closures

In December 2017, we announced the termination of a diagnostics research and development project in Europe. We recorded less than $0.1 million and less than $(0.1) million of adjustments in restructuring charges related to severance and employee benefits for the three and nine months ended September 30, 2019, respectively. From December 2017 to September 30, 2019, total expenses were $21.4 million.

In June 2018, we announced the closure of a small manufacturing operation in Munich, Germany. We recorded no adjustments and $(0.3) million of adjustments in restructuring charges related to severance and employee benefits for the three and nine months ended September 30, 2019, respectively. From June 2018 to September 30, 2019, total expenses were $1.4 million.

In December 2018, we announced the closure of a small manufacturing facility outside Paris, France. We recorded no adjustments and less than $(0.1) million of adjustments in restructuring charges related to severance and employee benefits for the three and nine months ended September 30, 2019, respectively. From December 2018 to September 30, 2019, total expenses were $4.1 million.

Restructuring charges for the termination of a diagnostics research and development project and the facility closures are all included in our Clinical Diagnostics segment's results of operations. The amounts recorded were reflected in Cost of goods sold of zero and $(0.2) million, and in Research and development expense of zero and $(0.1) million in the Condensed Consolidated Statements of Income for the three and nine months ended September 30, 2019, respectively. The liability of $3.5 million as of September 30, 2019 consisted of $1.4 million recorded in Accrued payroll and employee benefits, $0.2 million recorded in Other current liabilities, and $1.9 million recorded in Other long-term liabilities in the Condensed Consolidated Balance Sheets.

The following table summarizes the activity for the termination of the diagnostics research and development project and the facility closures restructuring reserves for severance and exit costs (in millions):



Balances as of December 31, 2018:	$	11.5
Adjustment to expense	(0.3		)
Cash payments	(7.4		)
Foreign currency translation gains	(0.3		)
Balances as of September 30, 2019:	$	3.5

14. LEASES

We have operating leases and to a lesser extent finance leases, for buildings, vehicles and equipment. Our leases have remaining lease terms of 1 year to 20 years, which includes our determination to exercise renewal options.

The components of lease expense were as follows (in millions):



	Three Months Ended		Nine Months Ended
	September 30,		September 30,
	2019		2019
Operating lease cost	$	14.2	$	38.7

Finance lease cost:
Amortization of right-of-use assets	$	0.1	$	0.5
Interest on lease liabilities	0.2		0.7
Total finance lease cost	$	0.3	$	1.2

Sublease income	$	0.7	$	2.2

The sublease is for a building with a term that ends in 2025, with no options to extend or renew.

Operating lease cost includes original right-of-use asset amortization, the impact of remeasurements, modifications, impairments and abandonments.

Supplemental cash flow information related to leases was as follows (in millions):



	Three Months Ended		Nine Months Ended
	September 30,		September 30,
	2019		2019
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$	11.6	$	34.5
Operating cash flows from finance leases	$	0.2	$	0.7
Financing cash flows from finance leases	$	0.1	$	0.5

Right-of-use assets obtained in exchange for lease obligations:
Operating leases	$	14.4	$	20.2
Finance leases	$	0.1	$	0.1

Supplemental balance sheet information related to leases was as follows (in millions):



	September 30, 2019

Operating Leases
Operating lease right-of-use assets	$	217.5

Current operating lease liabilities	$	33.7
Operating lease liabilities	192.6
Total operating lease liabilities	$	226.3



	September 30, 2019

Finance Leases
Property, plant and equipment, gross	$	11.4
Less: accumulated depreciation and amortization	(4.0		)
Property, plant and equipment, net	$	7.4

Current maturities of long-term debt and notes payable	$	0.5
Long-term debt, net of current maturities	11.2
Total finance lease liabilities	$	11.7



	September 30, 2019

Weighted Average Remaining Lease Term
Operating leases - in years	9
Finance leases - in years	18

Weighted Average Discount Rate
Operating leases	4.3	%
Finance leases	6.5	%

Maturities of lease liabilities were as follows (in millions):



Year Ending December 31,	Operating Leases			Finance Leases

2019 (excluding the nine months ended September 30, 2019)	$	11.1		$	1.2
2020	41.0			1.3
2021	35.4			1.2
2022	27.9			1.1
2023	24.3			1.1
Thereafter	141.3			15.4
Total lease payments	281.0			21.3
Less imputed interest	(54.7		)	(9.6		)
Total	$	226.3		$	11.7

The value of our operating lease portfolio is principally for facilities with longer durations than the lesser value vehicles and other equipment with shorter terms and higher-turn over.

Operating and Capital Lease Commitments Under ASC 840, Leases

Annual future minimum lease payments at December 31, 2018 under operating leases were as follows: 2019 - $44.4 million; 2020 - $37.8 million; 2021 - $27.4 million; 2022 - $19.7 million; 2023 - $13.9 million; and 2024 and beyond - $25.6 million.

The total minimum rentals to be received in the future for the sublease as of December 31, 2018 were $17.8 million and ends in 2025.

Maturities of our capital lease obligations at December 31, 2018 were as follows: 2019 - $0.5 million; 2020 - $0.2 million; 2021 - $0.5 million; 2022 - $0.4 million; 2023 - $0.4 million; thereafter - $9.9 million.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

This discussion should be read in conjunction with the information contained in both our Consolidated Financial Statements for the year ended December 31, 2018 and the Condensed consolidated financial statements for the three and nine months ended September 30, 2019.

Overview. We are a multinational manufacturer and worldwide distributor of our own life science research and clinical diagnostics products. Our business is organized into two reportable segments, Life Science and Clinical Diagnostics, with the mission to provide scientists with specialized tools needed for biological research and clinical diagnostics.

We sell more than 9,000 products and services to a diverse client base comprised of scientific research, healthcare, education and government customers worldwide. We do not disclose quantitative information about our different products and services as it is impractical to do so based primarily on the numerous products and services that we sell and the global markets that we serve.

We manufacture and supply our customers with a range of reagents, apparatus and equipment to separate complex chemical and biological materials and to identify, analyze and purify components. Because our customers require standardization for their experiments and test results, much of our revenues are recurring.

We are impacted by the support of many governments for both research and healthcare. The current global economic outlook is still uncertain as the need to control government social spending by many governments limits opportunities for growth. Adding to this uncertainty was the referendum in the United Kingdom to withdraw from the European Union. Approximately 40% of our year-to-date 2019 consolidated net sales are derived from the United States and approximately 60% are derived from international locations, with Europe being our largest international region. The international sales are largely denominated in local currencies such as the Euro, Swiss Franc, Japanese Yen, Chinese Yuan and British Sterling. As a result, our consolidated net sales expressed in dollars benefit when the U.S. dollar weakens and suffer when the dollar strengthens. When the U.S. dollar strengthens, we benefit from lower cost of sales from our own international manufacturing sites as well as non-U.S. suppliers, and from lower international operating expenses. We regularly discuss our changes in revenue and expense categories in terms of both changing foreign exchange rates and in terms of a currency neutral basis, if notable, to explain the impact currency has on our results.

In August 2019, we acquired all the issued and outstanding membership interests of a small U.S. manufacturer for approximately $60.0 million. Cash payments at closing, net of closing cash, were $59.7 million. The acquisition was included in our Clinical Diagnostics segment's results of operations from the acquisition date and was accounted for as a business combination. As of September 30, 2019, the preliminary allocation of the payments were $26.8 million to purchased intangibles consisting primarily of customer relationships, developed product technology and tradenames, $4.2 million to acquired net assets, and $28.7 million to goodwill. The purchase price allocation is preliminary as additional time is required to complete the valuation of assets acquired and liabilities assumed.

We believe that the acquisition will accelerate market penetration in the areas of quality controls and assay verification panels in our Clinical Diagnostics operations.

In March 2019, we completed the acquisition of all the issued and outstanding stock of a small U.S. private company for approximately $20.0 million. Cash payments, net of closing cash, consisted of $4.0 million paid in November 2018 and the remaining $16.0 million paid in March 2019. The acquisition was included in our Life Science segment's results of operations from the acquisition date and was accounted for as a business combination. The final allocation of the payments were $15.6 million to goodwill that included workforce and time-to-market advantage, $5.5 million to definite-lived intangibles, $0.2 million to in-process research and development, an indefinite-lived intangible asset, and a deferred tax liability of $1.3 million related to the purchased intangibles.

We believe that the acquisition will expand our reagents suite of offerings in our Life Science operations.

The following shows cost of goods sold, gross profit, expense items, change in fair market value of equity securities, and net income as a percentage of net sales:



	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2019		2018		2019		2018
Net sales	100.0	%	100.0	%	100.0	%	100.0	%
Cost of goods sold	45.2		47.4		45.1		46.8
Gross profit	54.8		52.6		54.9		53.2
Selling, general and administrative expense	36.0		36.9		36.2		37.1
Research and development expense	8.6		9.0		8.6		8.7
Change in fair market value of equity securities	(69.7	)	58.3		82.1		84.9
Net (loss) income	(46.2	)	49.4		71.4		71.4

Critical Accounting Policies and Estimates

An accounting policy is deemed to be critical if it requires an accounting estimate to be made based on assumptions about matters that are highly uncertain at the time the estimate is made, if different estimates reasonably could have been used, or if changes in the estimate that are reasonably likely to occur could materially impact the financial statements. Management believes that there have been no significant changes during the three and nine months ended September 30, 2019 to the items that we disclosed as our critical accounting policies and estimates in Management's Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K for the fiscal year ended December 31, 2018.

Other than the recent accounting pronouncement adoptions as discussed in Note 1 to the condensed consolidated financial statements, there have been no substantial changes in our significant accounting policies during the three and nine months ended September 30, 2019, compared with the significant accounting policies described in our Annual Report on Form 10-K for the year ended December 31, 2018.

Three Months Ended September 30, 2019 Compared to

Three Months Ended September 30, 2018

Results of Operations -- Sales, Margins and Expenses

Net sales (sales) for the third quarter of 2019 were $560.6 million compared to $545.1 million in the third quarter of 2018, an increase of 2.8%. Excluding the impact of foreign currency, third quarter 2019 sales increased by approximately 4.5% compared to the same period in 2018. Currency neutral sales increased in all three major regions, the Americas, Europe and Asia.

The Life Science segment reported sales for the third quarter of 2019 were $215.7 million, an increase of 4.5% compared to the same period last year. On a currency neutral basis, sales increased 5.7% compared to the third quarter in 2018. The currency neutral sales increase was primarily driven by double-digit growth in the Droplet Digital PCR and Food Safety products, as well as good demand within Gene Expression and Western Blotting product lines. Currency neutral sales increases occurred in all three major regions, the Americas, Asia, and Europe.

The Clinical Diagnostics segment reported sales for the third quarter of 2019 were $341.8 million, an increase of 2.4% compared to the same period last year. On a currency neutral basis, sales increased 4.3% compared to the third quarter in 2018. The currency neutral sales increase was primarily due to solid growth in our Quality Controls, Blood Typing, and Immunology product lines. On a geographic view, currency neutral sales growth for the third quarter was seen across all three major regions, with the strongest growth in Asia and the Americas.

Consolidated gross margins were 54.8% for the third quarter of 2019 compared to 52.6% for the third quarter of 2018. Life Science segment gross margins for the third quarter of 2019 increased from the prior year period by approximately 0.6 percentage points primarily due to a favorable mix driven by the Droplet Digital PCR and Gene Expression product lines. Clinical Diagnostics segment gross margins for the third quarter of 2019 increased by approximately 3.0 percentage points from the same period last year, driven by product mix along with lower excess and obsolete inventory related costs, and lower logistics costs.

Selling, general and administrative expenses (SG&A) increased to $201.6 million or 36.0% of sales for the third quarter of 2019 compared to $201.2 million or 36.9% of sales for the third quarter of 2018, relatively flat compared to the prior year period. Increases to SG&A were primarily related to employee related expenses of $12.8 million and contingent consideration of 4.0 million. These expenses were partially offset by decreases to lower professional fees of $10.4 million, lower bad debt expense of $6.8 million, and the strengthening of the U.S. dollar on foreign denominated expenses.

Research and development expense (R&D) decreased to $47.9 million or 8.6% of sales in the third quarter of 2019 compared to $49.2 million or 9.0% of sales in the third quarter of 2018. Life Science segment R&D was relatively flat for the third quarter of 2019 compared to the prior year period. Clinical Diagnostics segment R&D decreased in the third quarter of 2019 from the prior year period primarily from the timing of projects that led to lower spending for outside professional services, partially offset by an increase in employee related expenses.

Results of Operations – Non-operating

Interest expense for the third quarter of 2019 and 2018 was $5.5 million and $6.1 million, respectively, primarily due to slightly more capitalized interest in the third quarter of 2019 than in the prior year period.

Foreign currency exchange gains and losses consist primarily of foreign currency transaction gains and losses on intercompany net receivables and payables and the change in fair value of our forward foreign exchange contracts used to manage our foreign currency exchange risk. Foreign currency exchange net losses were $0.9 million for the third quarter of 2019 compared to $0.7 million for the third quarter of 2018. Gains and losses are primarily due to the estimating process inherent in the timing of product shipments and intercompany debt payments, market volatility, and the cost of hedging.

Change in fair market value of equity securities was a loss of $390.6 million compared to a gain of $318.0 million for the third quarter of 2019 and 2018, respectively, primarily resulting from the recognition of holding losses and gains on our investment in Sartorius AG.

Other (income) expense, net for the third quarter of 2019 was $4.4 million income compared to $2.6 million income for the third quarter of 2018 primarily due to higher investment income.

Our effective income tax rate was 23% for both the three months ended September 30, 2019 and 2018.

Our income tax returns are routinely audited by U.S. federal, state and foreign tax authorities. We are currently under examination by many of these tax authorities. There are differing interpretations of tax laws and regulations, and as a result, significant disputes may arise with these tax authorities involving issues of the timing and amount of deductions and allocations of income among various tax jurisdictions. We do not believe any currently pending uncertain tax positions will have a material adverse effect on our condensed consolidated financial statements, although an adverse resolution of one or more of these uncertain tax positions in any period may have a material impact on the results of operations for that period.

Nine Months Ended September 30, 2019 Compared to

Nine Months Ended September 30, 2018

Net sales (sales) for the first nine months of 2019 were $1.69 billion compared to $1.67 billion for the first nine months of 2018, an increase of 0.9%. Excluding the impact of foreign currency, the first nine months of 2019 sales increased by approximately 3.7% compared to the same period in 2018. Currency neutral sales increased in all three major regions, the Americas, Europe and Asia.

The Life Science segment sales for the first nine months of 2019 were $643.9 million, an increase of 3.5% compared to the same period last year. On a currency neutral basis, sales increased 5.7% compared to the first nine months of 2018. The currency neutral sales increase was primarily driven by growth in our Droplet Digital PCR, Protein Quantification, Process Chromatography, Gene Expression, Cell Biology, Antibody and Food Science product lines. Currency neutral sales increases occurred mostly in the Americas, but there was growth across all regions.

The Clinical Diagnostics segment sales for the first nine months of 2019 were $1.03 billion, a decrease of 0.6% compared to the same period last year. On a currency neutral basis, sales increased 2.7% compared to the first nine months of 2018. The currency neutral sales in the first nine months of 2018 benefited from a one-time $6.0 million receipt for the resolution of a licensed patent. Excluding the one-time receipt last year, we saw currency neutral sales growth across all three regions, the Americas, Europe and Asia. Product lines that contributed to the growth included Immunology, Quality Controls and Blood Typing. Management expects sales growth in Europe to continue to be challenging due to government initiatives to contain healthcare spending, along with increased competition.

Consolidated gross margins were 54.9% for the first nine months of 2019 compared to 53.2% for the first nine months of 2018. Life Science segment gross margins for the first nine months of 2019 increased from the prior year period by approximately 3.0 percentage points primarily due to the sales increases across most product lines, a $7.4 million cost of sales benefit from an escrow release related to an acquisition from 2011 within the Life Science group, product mix, as well as a decrease in service costs and warranty on instruments. Clinical Diagnostics segment gross margins for the first nine months of 2019 increased by approximately 0.8 percentage points from the same period last year, primarily driven by lower excess and obsolete inventory related costs, and lower logistics costs and royalty expense, partially offset by higher costs of service and warranty. The gross margin for the first nine months of 2018 benefited from a one-time receipt of $6.0 million for the resolution of a licensed patent, partially offset by a restructuring charge related to a manufacturing facility closure.

SG&A decreased to $610.5 million or 36.2% of sales for the nine months ended 2019 compared to $620.8 million or 37.1% of sales for the nine months ended 2018, an overall decrease of $10.3 million. Decreases to SG&A were primarily related to lower bad debt expense of $13.6 million, lower professional fees of $17.1 million, lower travel of $5.2 million, and other expenses of $5.5 million, including the impact of currency. These expenses were partially offset by increases in employee related expenses of $21.6 million, contingent consideration of $5.9 million and facilities of $3.6 million.

Research and development expense (R&D) decreased to $145.6 million or 8.6% of sales in the first nine months of 2019 compared to $146.1 million or 8.7% of sales in the first nine months of 2018. Life Science segment R&D increased in the first nine months of 2019 compared to the prior year period. The increase was primarily driven by additional spending for outside consultants and supplies of $4.0 million and $0.9 million, respectively. These expenses were related to new product innovation within the Droplet Digital PCR product line. Clinical Diagnostics segment R&D decreased in the first nine months of 2019 from the prior year period primarily from lower spending due to the timing of projects that led to lower outside professional services expense and lower R&D supplies expense, partially offset by an increase in employee related expenses.

Results of Operations – Non-operating

Interest expense for the first nine months of 2019 and 2018 were $17.4 million and $17.8 million for the first nine months of 2019 and 2018, respectively, relatively flat compared to the prior year period.

Foreign currency exchange net losses were $3.4 million and $1.9 million for the first nine months of 2019 and 2018, respectively. Gains and losses are primarily due to the estimating process inherent in the timing of product shipments and intercompany debt payments, market volatility, and the cost of hedging.

Change in fair market value of equity securities was a gain of $1.38 billion compared to a gain of $1.42 billion for the first nine months of 2019 and 2018, respectively, primarily resulting from the recognition of holding gains on our investment in Sartorius AG.

Other (income) expense, net for the first nine months of 2019 was $27.0 million income, compared to $29.6 million income for the first nine months of 2018. The decrease was primarily due to gains on a land sale of $4.1 million and a divestiture of a product line of $5.1 million that both occurred in the first quarter of 2018, partially offset by higher investment income and higher dividends from our investment in Sartorius AG compared to the prior year period.

Our effective income tax rate was 23% for both the first nine months of 2019 and 2018.

Liquidity and Capital Resources

Bio-Rad operates and conducts business globally, primarily through subsidiary companies established in the markets in which we trade. Goods are manufactured in a small number of locations, and are then shipped to local distribution facilities around the world. Our product mix is diversified, and certain products compete largely on product efficacy, while others compete on price. Gross margins are sufficient to exceed normal operating costs, and funding for research and development of new products, as well as routine outflows of capital expenditures, interest and taxes. In addition to the annual positive cash flow from operating activities, additional liquidity is readily available via the sale of short-term investments and access to our $200 million unsecured Credit Agreement that we entered into in April 2019, and to a lesser extent international lines of credit. Borrowings under the 2019 Credit Agreement are available on a revolving basis and can be used to make permitted acquisitions, for working capital and for other general corporate purposes. We had no outstanding borrowings under the 2019 Credit Agreement as of September 30, 2019, however, $0.2 million was utilized for domestic standby letters of credit that reduced our borrowing availability. The 2019 Credit Agreement matures in April 2024. In total under domestic and international lines of credit, standby letters of credit and guarantee arrangements, we had approximately $209.0 million available for borrowing and usage as of September 30, 2019, which was reduced by approximately $3.5 million that was utilized for standby letters of credit and guarantee arrangements issued by our banks to support our obligations. Management believes that this availability, together with cash flow from operations, will be adequate to meet our current objectives for operations, research and development, capital additions for manufacturing and distribution, plant and equipment, information technology systems and an acquisition of reasonable proportion to our existing total available capital.

At September 30, 2019, we had $979.2 million in cash, cash equivalents and short-term investments, of which approximately 20% was held in our foreign subsidiaries. We believe that our holdings of cash, cash equivalents and short-term investments in the U.S. and in our foreign subsidiaries are sufficient to meet both the current and long-term needs of our global operations. The amount of funds held in the United States can fluctuate due to the timing of receipts and payments in the ordinary course of business and due to other reasons, such as business-development activities. As part of our ongoing liquidity assessments, we regularly monitor the mix of domestic and foreign cash flows (both inflows and outflows).

It is generally our intention to repatriate certain foreign earnings to the extent that such repatriations are not restricted by local laws or accounting rules, and there are no substantial incremental costs.

Demand for our products and services could change more dramatically than in previous years based on activity, funding, reimbursement constraints and support levels from government, universities, hospitals and private industry, including diagnostic laboratories. The need for certain sovereign nations with large annual deficits to curtail spending, international trade disputes and increased regulation could lead to slower growth of, or even a decline in, our business. Sovereign nations either delaying payment for goods and services or renegotiating their debts could impact our liquidity.

Cash Flows from Operations

Net cash provided by operations was $298.1 million compared to $180.5 million for the nine months ended September 30, 2019 and 2018, respectively. The increase in operating cash flows was primarily the net effect of:


•	lower cash paid to suppliers and employees in 2019 that included lower payments for employee incentives and value added tax refunds of approximately $50 million,


•	lower income tax payments in 2019 compared to 2018, and


•	higher investment income received, partially offset by


•	forward foreign exchange contracts had lower net proceeds in 2019 compared to 2018.

Cash Flows from Investing Activities

Net cash used in investing activities was $147.7 million compared to $132.2 million for the nine months ended September 30, 2019 and 2018, respectively. Purchases, sales and maturities of marketable securities and investments combined had an overall increase of $65.3 million primarily due to higher maturities and sales, and lower purchases.

Our investment objective is to maintain liquidity to meet anticipated operational and other corporate requirements in which capital is preserved and increased through investing in low risk, high quality securities with commensurate returns, consistent with our risk tolerance level.

During the first quarter of 2019, we received $7.4 million from an escrow release related to an acquisition from 2011 within the Life Science Group. During the first quarter of 2018, we received $6.9 million for a divestiture of a product line and $4.1 million for a land sale.

In August 2019, we acquired all the issued and outstanding membership interests of a small U.S. manufacturer for approximately $60.0 million. Cash payments at closing, net of closing cash, were $59.7 million. The acquisition does not meet the significant or material subsidiary test. The purchase price allocation is preliminary as additional time is required to complete the valuation of assets acquired and liabilities assumed.

We continue to review possible acquisitions, including early stage businesses, to expand both our Life Science and Clinical Diagnostics segments. We routinely meet with the principals or brokers of the subject companies. However, it is not certain at this time that any of these discussions will advance to completion.

Capital expenditures totaled $76.9 million and $76.0 million for the nine months ended September 30, 2019 and 2018, respectively. Capital expenditures represent the addition and replacement of production machinery and research equipment, ongoing manufacturing and facility additions for expansion, regulatory, environmental and compliance. Also included in capital expenditures are investments in business systems and data communication upgrades and enhancements, including the remaining phases of the global enterprise resource planning (ERP) platform. All periods include equipment placed with Clinical Diagnostics segment customers who then contract to purchase our reagents for use.

Cash Flows from Financing Activities

Net cash used in financing activities was $18.0 million compared to $1.7 million for the nine months ended September 30, 2019 and 2018, respectively. Net cash used in the nine months ended September 30, 2019 was primarily due to the repurchase of our common stock for $20.0 million under our repurchase program as described in Part II, Item 2, Unregistered Sales of Equity Securities and Use of Proceeds during the third and second quarters of 2019 of $5.0 million and $15.0 million, respectively. Net cash used in the nine months ended September 30, 2019 compared to the nine months ended September 30, 2018 was partially offset by the net proceeds of $3.8 million in the first quarter of 2019 from the reissuance of treasury stock for share-based compensation as described below under Treasury Shares.

We have outstanding Senior Notes of $425 million, which are not due until December of 2020. We believe the current cash is sufficient to meet normal operating costs, and funding for research and development of new products, as well as routine outflows of capital expenditures, interest and taxes.

Treasury Shares

During the third quarter of 2019, 117,833 of Class A treasury stock and 917 of Class B treasury stock, with an aggregate total cost of $33.3 million, was reissued to fulfill annual grants to employees under our restricted stock program. Upon reissuing the Class A and Class B treasury stock, a loss of $8.4 million was incurred as they were reissued at a lower price than their average cost, which reduced Retained earnings while $24.9 million reduced Additional paid-in capital. These reissues did not require cash payments or receipts and therefore did not affect liquidity.

During the first quarter of 2019, 19,755 of Class A treasury stock with an aggregate total cost of $5.4 million was reissued to fulfill our Employee Stock Purchase Plan purchases. A loss of $1.6 million was incurred upon reissuing the Class A treasury stock as they were reissued at a lower price than their average cost, which reduced Retained earnings and resulted in net proceeds of $3.8 million.

Recent Accounting Pronouncements Adopted and to be Adopted

See Note 1 to the condensed consolidated financial statements for recent accounting pronouncements adopted and to be adopted.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

During the nine months ended September 30, 2019, there have been no material changes from the disclosures about market risk provided in our Annual Report on Form 10-K for the year ended December 31, 2018.

Item 4. Controls and Procedures

Disclosure Controls and Procedures

We maintain “disclosure controls and procedures,” as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (“Exchange Act”), that are designed to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in Securities and Exchange Commission rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer ("CEO") and Chief Financial Officer ("CFO"), as appropriate, to allow for timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, management recognized that disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Additionally, in designing disclosure controls and procedures, our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures. The design of any disclosure controls and procedures also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

Subject to the limitations noted above, our management, with the participation of our CEO and CFO, has evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of the period covered by this Quarterly Report on Form 10-Q. Based on that evaluation, the CEO and CFO have concluded that, as of such date, our disclosure controls and procedures were effective to meet the objective for which they were designed and operate at the reasonable assurance level.

Changes to Internal Control Over Financial Reporting

We identified no changes in internal control over financial reporting that occurred during our quarter ended September 30, 2019 that have materially affected, or that are reasonably likely to materially affect, our internal control over financial reporting.

PART II – OTHER INFORMATION

Item 1. Legal Proceedings

See Note 12, “Legal Proceedings” in the Notes to Condensed Consolidated Financial Statements of Part I, Item 1 of this Quarterly Report on Form 10-Q.

Item 1A. Risk Factors

Our settlement with government agencies in connection with violations by us of the U.S. Foreign Corrupt Practices Act could have a material adverse effect on our business, results of operations and financial condition.

As previously disclosed, we entered into a non-prosecution agreement (NPA) with the U.S. Department of Justice (DOJ) and the Securities and Exchange Commission (SEC) and consented to the entry of an Order by the SEC (SEC Order), effective November 3, 2014, which actions resolved both the DOJ and the SEC investigations into our violations of the U.S. Foreign Corrupt Practices Act (FCPA). Under the terms of the NPA and the SEC Order, we agreed to pay a financial penalty and certain amounts in disgorgement and interest as well as to compliance, reporting and cooperation obligations to be performed for two years. On October 28, 2016, the DOJ and SEC informed Bio-Rad that they did not intend to extend the NPA after it expired November 2, 2016.

Whether by virtue of disclosure of the NPA and the SEC Order or otherwise, we may be subject to investigations by foreign governments or further claims by third parties arising from conduct subject to the investigation or our other international operations. Many of our customers in our significant international operations are government agencies or state-owned or state-controlled universities, hospitals and laboratories. The disclosure of the NPA and the SEC Order and any further violations of the FCPA could harm our reputation with these customers, which could materially adversely affect our business, results of operations and financial condition. Any further violations of the FCPA also could result in more punitive actions by the SEC and DOJ, which also could materially adversely affect our business, results of operations and financial condition.

Our international operations expose us to additional costs and legal and regulatory risks, which could have a material adverse effect on our business, results of operations and financial condition.

We have significant international operations. We have direct distribution channels in over 35 countries outside the United States, and during the first nine months of 2019 our foreign entities generated 60% of our net sales. Compliance with complex foreign and U.S. laws and regulations that apply to our international operations increases our cost of doing business. These numerous and sometimes conflicting laws and regulations include, among others, data privacy requirements (including the requirements for compliance with the EU General Data Protection Regulation, which went into effect May 25, 2018), labor relations laws, tax laws, anti-competition regulations, import and trade restrictions, tariffs, duties, quotas and other trade barriers, export requirements, U.S. laws such as the FCPA and other U.S. federal laws and regulations established by the office of Foreign Asset Control, foreign laws such as the UK Bribery Act 2010 or other foreign laws which prohibit corrupt payments to governmental officials or certain payments or remunerations to customers. In addition, changes in laws or regulations potentially could be disruptive to our operations and business relationships in the affected regions. For example, the United Kingdom's anticipated withdrawal from the European Union (commonly referred to as “Brexit”) could disrupt the free movement of goods, services and people between the United Kingdom and the European Union and result in increased regulatory, legal, labor and tax complexities.

Given the high level of complexity of the foreign and U.S. laws and regulations that apply to our international operations, there is a risk that we may inadvertently breach some provisions, for example, through fraudulent or negligent behavior of individual employees, our failure to comply with certain formal documentation requirements, or otherwise. Our success depends, in part, on our ability to anticipate these risks and manage these challenges through policies, procedures and internal controls. However, we have a dispersed international sales organization, and we use distributors and agents in many of our international operations. This structure makes it more difficult for us to ensure that our international selling operations comply with laws and regulations, and our global policies and procedures.

Violations of these laws and regulations could result in fines, criminal sanctions against us, our officers or our employees, requirements to obtain export licenses, cessation of business activities in sanctioned countries, implementation of compliance programs, and prohibitions on the conduct of our business. Violations of laws and regulations also could result in prohibitions on our ability to offer our products in one or more countries and could materially damage our reputation, our brand, our international expansion efforts, our ability to attract and retain employees, or our business, results of operations and financial condition. See also our risk factors regarding government regulations and regarding global economic conditions below.

The industries and market segments in which we operate are highly competitive, and we may not be able to compete effectively.

The life science and clinical diagnostics markets are each highly competitive. Some of our competitors have merged, and some of our competitors have greater financial resources than we do, making them better equipped to license technologies and intellectual property from third parties or to fund research and development, manufacturing and marketing efforts. Moreover, competitive and regulatory conditions in many markets in which we operate restrict our ability to fully recover, through price increases, higher costs of acquired goods and services resulting from inflation and other drivers of cost increases. Many public tenders have become more competitive due to governments lengthening the commitments of their public tenders to multiple years, which reduce the number of tenders in which we can participate annually. Because the value of these multiple-year tenders is so high, our competitors have been more aggressive with their pricing. Our failure to compete effectively and/or pricing pressures resulting from competition could adversely affect our business, results of operations and financial condition.

We may not be able to grow our business because of our failure to develop new or improved products.

Our future growth depends in part on our ability to continue to improve our product offerings and develop and introduce new product lines and extensions that integrate technological advances. In particular, we may not be able to keep up with changes in the clinical diagnostics industry, such as the trend toward molecular diagnostics or point-of-care tests. If we are unable to integrate technological advances into our product offerings or to design, develop, manufacture and market new product lines and extensions successfully and in a timely manner, our business, results of operations and financial condition will be adversely affected. We have experienced product launch delays in the past, and may do so in the future. We cannot assure you that our product and process development efforts will be successful or that new products we introduce will achieve market acceptance. Failure to launch successful new products or improvements to existing products may cause our products to become obsolete, which could harm our business, results of operations and financial condition.

We are subject to foreign currency exchange fluctuations, which could have a material adverse effect on our results of operations and financial condition.

As stated above, a significant portion of our operations and sales are outside of the United States. When we make purchases and sales in currencies other than the U.S. dollars, we are exposed to fluctuations in foreign currencies relative to the U.S. dollar that may adversely affect our results of operations and financial condition. Our international sales are largely denominated in local currencies. As a result, the strengthening of the U.S. dollar negatively impacts our consolidated net sales expressed in U.S. dollars. Conversely, when the U.S. dollar weakens, our expenses at our international sites increase. In addition, the volatility of other currencies may negatively impact our operations outside of the United States and increase our costs to hedge against currency fluctuations. We cannot assure you that future shifts in currency exchange rates will not have a material adverse effect on our results of operations and financial condition.

We may experience difficulties implementing our new global enterprise resource planning system.

We are engaged in a multi-year implementation of a new global enterprise resource planning system (ERP). The ERP is designed to efficiently maintain our books and records and provide information important to the operation of our business to our management team. The ERP will continue to require significant investment of human and financial resources. In implementing the ERP, we may experience significant delays, increased costs and other difficulties. Any significant disruption or deficiency in the design and implementation of the ERP could adversely affect our ability to process orders, ship product, send invoices and track payments, fulfill contractual obligations or otherwise operate our business. For example, we experienced system implementation issues in our Clinical Diagnostics segment during our first deployment that impacted invoicing and caused an increase in accounts receivable. In our second deployment, we experienced delays in manufacturing and logistics, which adversely impacted our sales. In our third deployment in Western Europe in April 2017 we experienced system implementation issues impacting the timing of payment of vendor invoices and resulting in delays in product availability and shipments. We also experienced lower productivity levels related to the April 2017 go-live of the ERP in Western Europe, which adversely impacted our sales during the second and third quarters of 2017. We expect to implement the remaining smaller phases of the ERP platform over the next few years. In addition, our efforts to centralize various business processes and functions within our organization in connection with our ERP implementation may continue to disrupt our operations and negatively impact our business, results of operations and financial condition.

Recent and planned changes to our organizational structure and executive management team could negatively impact our business.

We made significant changes to our organizational structure over the past few years. In 2016, we began implementing the reorganization of the structure of our European organization, and we have continued implementing this reorganization in 2017, 2018 and 2019. The Board of Directors appointed a new Chief Operating Officer effective April 22, 2019 and a new Chief Financial Officer effective April 6, 2019. These changes may have unintended consequences, such as distraction of our management and employees, business disruption, attrition of our workforce, inability to attract or retain key employees, and reduced employee morale or productivity.

Our failure to establish and maintain effective internal control over financial reporting could result in material misstatements in our financial statements, our failure to meet our reporting obligations and cause investors to lose confidence in our reported financial information, which in turn could cause the trading price of our common stock to decline.

Maintaining effective disclosure controls and procedures and internal controls over financial reporting are necessary for us to produce reliable financial statements.

As previously discussed in Item 9A "Controls and Procedures" of our Annual Report for the period ended December 31, 2017, and Item 4 "Controls and Procedures" of our 2018 Form 10-Q's, management identified a material weakness in our internal control over financial reporting. During the fourth quarter of 2017 and throughout 2018, management conducted an extensive remediation plan to address its material weakness and management concluded that the material weakness had been remediated as of December 31, 2018. However, we cannot assure you that additional deficiencies or material weaknesses in our internal control over financial reporting will not be identified in the future.

Material weaknesses have adversely affected us in the past and could affect us in the future, and the results of our periodic management evaluations and annual auditor attestation reports regarding the effectiveness of our internal control over financial reporting required by Section 404 of the Sarbanes-Oxley Act of 2002. Any failure to maintain or implement new or improved internal controls, or any difficulties that we may encounter in their maintenance or implementation, could result in additional significant deficiencies or material weaknesses, result in material misstatements in our consolidated financial statements and cause us to fail to meet our reporting obligations. This could cause us to lose public confidence, and could cause the trading price of our common stock to decline. For further information regarding our controls and procedures, see Part I, Item 4 of this Quarterly Report on Form 10-Q.

Breaches of our information systems could have material adverse effect on our business and results of operations.

Through our sales and eCommerce channels, we collect and store confidential information that customers provide to, among other things, purchase products or services, enroll in promotional programs and register on our Web site. We also acquire and retain information about suppliers and employees in the normal course of business. Such information on our systems includes personally identifiable information and, in limited instances, protected health information. We also create and maintain proprietary information that is critical to our business, such as our product designs and manufacturing processes. Despite recent initiatives to improve our technology systems, such as our enterprise resource planning implementation and the centralization of our global information technology organization, we could experience a significant data security breach. Computer hackers may attempt to penetrate our or our vendors’ information systems and, if successful, misappropriate confidential customer, supplier, employee or other business information, such as our intellectual property. Third parties could also gain control of our systems and use them for criminal purposes while appearing to be us. As a result, we could lose existing customers, have difficulty attracting new customers, be exposed to claims from customers, financial institutions, payment card associations, employees and other persons, have regulatory sanctions or penalties imposed, incur additional expenses or lose revenues as a result of a data privacy breach, or suffer other adverse consequences. Our operations and ability to process sales orders, particularly through our eCommerce channels, could also be disrupted. Any significant breakdown, intrusion, interruption, corruption, or destruction of our systems, as well as any data breaches, could have a material adverse effect on our business and results of operations. See also our risk factors regarding our ERP implementation above and our information technology systems below.

Risks relating to intellectual property rights may negatively impact our business.

We rely on a combination of copyright, trade secret, patent and trademark laws and third-party nondisclosure agreements to protect our intellectual property rights and products. However, we cannot assure you that our intellectual property rights will not be challenged, invalidated, circumvented or rendered unenforceable, or that meaningful protection or adequate remedies will be available to us. For instance, unauthorized third parties have attempted to copy our intellectual property, reverse engineer or obtain and use information that we regard as proprietary, or have developed equivalent technologies independently, and may do so in the future. Additionally, third parties have asserted patent, copyright and other intellectual property rights to technologies that are important to us, and may do so in the future. If we are unable to license or otherwise access protected technology used in our products, or if we lose our rights under any existing licenses, we could be prohibited from manufacturing and marketing such products. From time to time, we also must enforce our patents or other intellectual property rights or defend ourselves against claimed infringement of the rights of others through litigation. As a result, we could incur substantial costs, be forced to redesign our products, or be required to pay damages to an infringed party. Any of the foregoing matters could adversely impact our business, results of operations and financial condition.

Global economic and geopolitical conditions could adversely affect our operations.

In recent years, we have been faced with very challenging global economic conditions. A deterioration in the global economic environment may result in decreased demand for our products, increased competition, downward pressure on the prices for our products and longer sales cycles. A weakening of macroeconomic conditions may also adversely affect our suppliers, which could result in interruptions in supply in the future. We have also experienced delays in collecting receivables in certain countries in Western Europe, and we may experience similar delays in these and other countries or regions experiencing liquidity problems. In addition, a slowing of growth in the Chinese economy and in emerging markets, especially those oil-producing countries that would be affected by a decline in oil prices, could adversely affect our business, results of operations or financial condition. There is also uncertainty surrounding the impact that Brexit will have on European and worldwide economic conditions and the stability of global financial markets, and a negative effect from any of these things could adversely affect our business, results of operations or financial condition. Additionally, the United States and other countries, such as China and India, recently have imposed tariffs on certain goods. While tariffs imposed by other countries, such as China and India, on U.S. goods have not yet had a significant impact on our business, further escalation of tariffs or other trade barriers could adversely impact our profitability and/or our competitiveness. In addition, the geopolitical situation in locations such as the Middle East could adversely affect our business in such locations.

See also our risk factors regarding our international operations above and regarding government regulations below.

Reductions in government funding and the capital spending programs of our customers could have a material adverse effect on our business, results of operations or financial condition.

Our customers include universities, clinical diagnostics laboratories, government agencies, hospitals and pharmaceutical, biotechnology and chemical companies. The capital spending programs of these institutions and companies have a significant effect on the demand for our products. Such programs are based on a wide variety of factors, including the resources available to make such purchases, the availability of funding from grants by governments or government agencies, the spending priorities for various types of equipment and the policies regarding capital expenditures during industry downturns or recessionary periods. If government funding to our customers were to decrease, or if our customers were to decrease or reallocate their budgets in a manner adverse to us, our business, results of operations or financial condition could be materially and adversely affected.

Changes in the healthcare industry could have an adverse effect on our business, results of operations and financial condition.

There have been, and will continue to be, significant changes in the healthcare industry in an effort to reduce costs. These changes include:

•

The trend towards managed care, together with healthcare reform of the delivery system in the United States and efforts to reform in Europe, has resulted in increased pressure on healthcare providers and other participants in the healthcare industry to reduce selling prices. Consolidation among healthcare providers and consolidation among other participants in the healthcare industry has resulted in fewer, more powerful groups, whose purchasing power gives them cost containment leverage. In particular, there has been a consolidation of laboratories and a consolidation of blood transfusion centers. These industry trends and competitive forces place constraints on the levels of overall pricing, and thus could have a material adverse effect on our gross margins for products we sell in clinical diagnostic markets.

•

Third party payors, such as Medicare and Medicaid in the United States, have reduced their reimbursements for certain medical products and services. Our Clinical Diagnostics business is impacted by the level of reimbursement available for clinical tests from third party payors. In the United States payment for many diagnostic tests furnished to Medicare fee-for-service beneficiaries is made based on the Medicare Clinical Laboratory Fee Schedule (CLFS), a fee schedule established and adjusted from time to time by the Centers for Medicare and Medicaid Services (CMS). Some commercial payors are guided by the CLFS in establishing their reimbursement rates. Laboratories and clinicians may decide not to order or perform certain clinical diagnostic tests if third party payments are inadequate, and we cannot predict whether third party payors will offer adequate reimbursement for tests utilizing our products to make them commercially attractive. Legislation, such as the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (PPACA) and the Middle Class Tax Relief and Job Creation Act of 2012, has reduced the payments for clinical laboratory services paid under the CLFS. In addition, the Protecting Access to Medicare Act of 2014 (PAMA) has made significant changes to the way Medicare will pay for clinical laboratory services, which has further reduced reimbursement rates.

•

The PPACA has also imposed a 2.3% excise tax on the sales of certain medical devices in the U.S., which we are required to pay on most of our United States Clinical Diagnostic sales. However, the Consolidated Appropriations Act, 2016 (Pub. L. 114-113), signed into law on December 18, 2015, included a two year moratorium on the medical device excise tax. On January 22, 2018, the moratorium on the medical device excise tax was further extended until January 1, 2020.

To the extent that the healthcare industry seeks to address the need to contain costs stemming from reform measures such as those contained in the PPACA and the PAMA, or in future legislation, by limiting the number of clinical tests being performed or the amount of reimbursement available for such tests, our business, results of operations and financial condition could be adversely affected. If these changes in the healthcare markets in the United States and Europe continue, we could be forced to alter our approach in selling, marketing, distributing and servicing our products.

We are subject to substantial government regulation, and any changes in regulation or violations of regulations by us could adversely affect our business, prospects, results of operations or financial condition.

Some of our products (primarily our Clinical Diagnostic products), production processes and marketing are subject to U.S. federal, state and local, and foreign regulation, including by the FDA in the United States and its foreign counterparts. The FDA regulates our Clinical Diagnostic products as medical devices, and we are subject to significant regulatory clearances or approvals to market our Clinical Diagnostic products and other requirements including, for example, recordkeeping and reporting requirements, such as the FDA’s medical device reporting regulations and reporting of corrections and removals. The FDA has broad regulatory and enforcement powers. If the FDA determines that we have failed to comply with applicable regulatory requirements, it can impose a variety of enforcement actions ranging from public warning letters, fines, injunctions, consent decrees and civil penalties to suspension or delayed issuance of approvals, seizure or recall of our products, total or partial shutdown of production, withdrawal of approvals or clearances already granted, and criminal prosecution.

The FDA can also require us to repair, replace or refund the cost of devices that we manufactured or distributed.

In addition, the FDA may change its clearance and approval policies, adopt additional regulations or revise existing regulations, or take other actions, which may prevent or delay approval or clearance of our products or impact our ability to modify our currently approved or cleared products on a timely basis. Changes in the FDA’s review of certain clinical diagnostic products referred to as laboratory developed tests, which are tests developed by a single laboratory for use only in that laboratory, could affect some of our customers who use our Life Science instruments for laboratory developed tests. In the past, the FDA has chosen to not enforce applicable regulations and has not reviewed such tests for approval. However, the FDA has issued draft guidance that it may begin enforcing its medical device requirements, including premarket submission requirements, to such tests. Any delay in, or failure to receive or maintain, clearance or approval for our products could prevent us from generating revenue from these products and adversely affect our business operations and financial results. Additionally, the FDA and other regulatory authorities have broad enforcement powers. Regulatory enforcement or inquiries, or other increased scrutiny on us, could affect the perceived safety and efficacy of our products and dissuade our customers from using our products.

Many foreign governments have similar rules and regulations regarding the importation, registration, labeling, sale and use of our products. Such agencies may also impose new requirements that may require us to modify or re-register products already on the market or otherwise impact our ability to market our products in those countries. For example, in April 2017 the European Parliament voted to enact final regulations that include broad changes regarding in vitro diagnostic devices and medical devices, which will require us to modify or re-register some products and will result in additional costs. In addition, Russia has enacted more stringent medical product registration and labeling regulations, China has enacted stricter labeling requirements, and we expect other countries, such as Brazil and India, to impose more regulations that impact our product registrations. Brexit also will likely result in additional regulatory requirements associated with goods sold in the United Kingdom and will likely result in additional complexities and possible delays with respect to goods, raw materials and personnel moving between the United Kingdom and the European Union. In addition, new government administrations may interpret existing regulations or practices differently. For example, the Mexican health regulatory agency COFEPRIS recently cited Bio-Rad’s Mexican subsidiary for operating practices that had been endorsed by a prior administration, which has impacted Bio-Rad’s ability to conduct its Clinical Diagnostics business in Mexico. Due to these evolving and diverse requirements, we face uncertain product approval timelines, additional time and effort to comply, as well as the potential for reduced sales and/or fines for noncompliance. Increasing protectionism in such countries also impedes our ability to compete with local companies. For example, we may not be able to participate in certain public tenders in Russia because of increasing measures to restrict access to such tenders for companies without local manufacturing capabilities. Such regulations could adversely affect our business, results of operations and financial condition. See also our risk factors regarding our international operations and regarding global economic and geopolitical conditions above.

We are also subject to government regulation of the use and handling of a number of materials and controlled substances. The U.S. Drug Enforcement Administration establishes registration, security, recordkeeping, reporting, storage, distribution and other requirements for controlled substances pursuant to the Controlled Substances Act of 1970. Failure to comply with present or future laws and regulations could result in substantial liability to us, suspension or cessation of our operations, restrictions on our ability to expand at our present locations or require us to make significant capital expenditures or incur other significant expenses.

We cannot assure you that we will be able to integrate acquired companies, products or technologies into our company successfully, or we may not be able to realize the anticipated benefits from the acquisitions.

As part of our overall business strategy, we pursue acquisitions of and investments in complementary companies, products and technologies. In order to be successful in these activities, we must, among other things:


•	assimilate the operations and personnel of acquired companies;


•	retain acquired business customers;


•	minimize potential disruption to our ongoing business;


•	retain key technical and management personnel;


•	integrate acquired companies into our strategic and financial plans;


•	accurately assess the value of target companies, products and technologies;


•	comply with new regulatory requirements;


•	harmonize standards, controls, procedures and policies;


•	minimize the impact to our relationships with our employees and customers; and


•	assess, document and remediate any deficiencies in disclosure controls and procedures and internal control over financial reporting.

The benefits of any acquisition may prove to be less than anticipated and may not outweigh the costs reported in our financial statements. Completing any potential future acquisitions could cause significant diversion of our management’s time and resources. If we acquire new companies, products or technologies, we may be required to assume contingent liabilities or record impairment charges for goodwill and other intangible assets over time. Goodwill and non-amortizable intangible assets are subject to impairment testing, and potential periodic goodwill impairment charges, amortization expenses related to certain intangible assets, and other write-offs could harm our operating results. Impairment tests are highly sensitive to changes in assumptions and minor changes to assumptions could result in impairment losses. If the results forecast in our impairment tests are not achieved, or business trends vary from the assumptions used in forecasts, or external factors change detrimentally, future impairment losses may occur. For example, as we previously discussed in Item 7 of our Annual Report for the period ended December 31, 2017, one reporting unit, whose goodwill was primarily from the acquisitions of Biotest AG and DiaMed Holding AG, had excess fair value over book value of only 8% at December 31, 2017. The goodwill allocated to this reporting unit as of December 31, 2017 was $263.6 million. We impaired all the goodwill related to this reporting unit for the year ended December 31, 2018 because assumptions utilized in our 2017 forecast did not materialize.

We cannot assure you that we will successfully overcome these risks or any other problems we encounter in connection with any acquisitions, and any such acquisitions could adversely affect our business, results of operations and financial condition.

Product quality and liability issues could harm our reputation and negatively impact our business, results of operations and financial condition.

We must adequately address quality issues associated with our products, including defects in our engineering, design and manufacturing processes, as well as defects in third-party components included in our products. Our instruments, reagents and consumables are complex, and identifying the root cause of quality issues, especially those affecting reagents or third-party components, is difficult. We may incur significant costs and expend substantial time in researching and remediating such issues. Quality issues could also delay our launching or manufacturing of new products. In addition, quality issues, unapproved uses of our products, or inadequate disclosure of risks related to our products, could result in product recalls or product liability or other claims being brought against us. These issues could harm our reputation, impair our relationship with existing customers and harm our ability to attract new customers, which could negatively impact our business, results of operations and financial condition.

Lack of key personnel could hurt our business.

Our products are very technical in nature. In general, only highly qualified and well-trained scientists have the necessary skills to develop, market and sell our products, and many of our manufacturing positions require very specialized knowledge and skills. In addition, the global nature of our business also requires that we have sophisticated and experienced staff to comply with increasingly complex international laws and regulations. We face intense competition for these professionals from our competitors, customers, marketing partners and other companies throughout our industry. In particular, the job market in Northern California, where many of our employees are located, is very competitive. If we do not offer competitive compensation and benefits, we may fail to retain or attract a sufficient number of qualified personnel, which could impair our ability to properly run our business.

In some cases we rely on temporary personnel or consultants, and we may do so in the future. Such temporary personnel or consultants may lack the knowledge and/or specific skills necessary for our business, require time to train without benefiting us through extended employment and increase our costs. In addition, as noted above, our strategic initiatives, such as our internal restructuring and ERP implementation, may be burdensome and disruptive and lead to employee dissatisfaction and attrition.

A reduction or interruption in the supply of components and raw materials could adversely affect our manufacturing operations and related product sales.

The manufacture of many of our products requires the timely delivery of sufficient amounts of quality components and materials. We manufacture our products in numerous manufacturing facilities around the world. We acquire our components and materials from many suppliers in various countries. We work closely with our suppliers to ensure the continuity of supply but we cannot guarantee these efforts will always be successful. Further, while we seek to diversify our sources of components and materials, in certain instances we acquire components and materials from a sole supplier. In addition, due to the regulatory environment in which we operate, we may be unable to quickly establish additional or replacement sources for some components or materials. If our supply is reduced or interrupted or of poor quality, and we are unable to develop alternative sources for such supply, our ability to manufacture our products in a timely or cost-effective manner could be adversely affected, which would adversely affect our ability to sell our products.

If our information technology systems are disrupted, or if we fail to successfully implement, manage and integrate our information technology and reporting systems, our business, results of operations and financial condition could be harmed.

Our information technology (IT) systems are an integral part of our business, and a serious disruption of our IT systems could have a material adverse effect on our business, results of operations and financial condition. We depend on our IT systems to process orders, manage inventory and collect accounts receivable. Our IT systems also allow us to efficiently purchase products from our suppliers and ship products to our customers on a timely basis, maintain cost-effective operations and provide customer service. We may experience disruption of our IT systems due to redundancy issues with our network servers. We cannot assure you that our contingency plans will allow us to operate at our current level of efficiency.

Our ability to implement our business plan in a rapidly evolving market requires effective planning, reporting and analytical processes. We expect that we will need to continue to improve and further integrate our IT systems, reporting systems and operating procedures by training and educating our employees with respect to these improvements and integrations on an ongoing basis in order to effectively run our business. We may suffer interruptions in service, loss of data or reduced functionality when we upgrade or change systems. If we fail to successfully manage and integrate our IT systems, reporting systems and operating procedures, it could adversely affect our business, results of operations and financial condition. See also our risk factors regarding our ERP implementation and data security above and events beyond our control below.

Natural disasters, terrorist attacks, acts of war or other events beyond our control may cause damage or disruption to us and our employees, facilities, information systems, security systems, vendors and customers, which could significantly impact our business, results of operations and financial condition.

We have significant manufacturing and distribution facilities, including in the western United States, France, Switzerland, Germany and Singapore. In particular, the western United States has experienced a number of earthquakes, wildfires, floods, landslides and other natural disasters in recent years. These occurrences could damage or destroy our facilities which may result in interruptions to our business and losses that exceed our insurance coverage. In addition, electricity outages, strikes or other labor unrest at any of our sites or surrounding areas could cause disruption to our business.

Acts of terrorism, bioterrorism, violence or war could also affect the markets in which we operate, our business operations and strategic plans. Political unrest may affect our sales in certain regions, such as in Southeast Asia, the Middle East and Eastern Europe. Any of these events could adversely affect our business, results of operations and financial condition.

We may have higher than anticipated tax liabilities.

We are subject to income taxes in the United States and many foreign jurisdictions. We report our results of operations based on our determination of the amount of taxes owed in various tax jurisdictions in which we operate. The determination of our worldwide provision for income taxes and other tax liabilities requires estimation, judgment and calculations where the ultimate tax determination may not be certain. Our determination of our tax liabilities is subject to review or examination by tax authorities in various tax jurisdictions. Tax authorities have disagreed with our judgment in the past and may disagree with positions we take in the future resulting in assessments of additional taxes. Any adverse outcome of such review or examination could have a negative impact on our operating results and financial condition.

Economic and political pressures to increase tax revenues in various jurisdictions may make resolving tax disputes more difficult. For example, in recent years, the tax authorities in Europe have disagreed with our tax positions related to hybrid debt, research and development credits, transfer pricing and indirect taxes, among others. We regularly assess the likelihood of the outcome resulting from these examinations to determine the adequacy of our provision for income taxes. Although we believe our tax estimates are reasonable, the final determination of tax audits and any related litigation could be materially different from our historical income tax provisions and accruals.

The results from various tax examinations, audits and litigation may differ from the liabilities recorded in our financial statements and could materially and adversely affect our financial results and cash flows in the periods in which those determinations are made.

Changes in tax laws or rates, changes in the interpretation of tax laws or changes in the jurisdictional mix of our earnings could adversely affect our financial position and results of operations.

On December 22, 2017, the U.S. enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act (the “Tax Act”) which made a number of substantial changes to how the United States imposes income tax on multinational corporations. The U.S Treasury, Internal Revenue Service and other standard setting bodies continue to issue guidance and interpretation relating to the Tax Act. As future guidance is issued, we may make adjustments to amounts previously reported that could materially impact our financial statements.

Our global operations subject us to income and other taxes in the U.S. and in numerous foreign jurisdictions, each with different tax schemes and tax rates. In addition to the changes in tax laws and the interpretation of tax laws and tax rates in these jurisdictions, the jurisdictional mix of our earnings in countries with differing statutory tax rates can have a significant impact on our effective tax rate from period to period.

The tax effect of our investment in Sartorius AG and the jurisdictional mix of our earnings could continue to materially affect our financial results and cash flow.

In addition, the adoption of some or all of the recommendations set forth in the Organization for Economic Co-operation and Development’s project on “Base Erosion and Profit Shifting” (BEPS) by tax authorities in the countries in which we operate, could negatively impact our effective tax rate. These recommendations focus on payments from affiliates in high tax jurisdictions to affiliates in lower tax jurisdictions and the activities that give rise to a taxable presence in a particular country.

Our reported financial results may be materially affected by changes in accounting principles generally accepted in the United States.

Generally accepted accounting principles in the United States, or U.S. GAAP, are subject to interpretation by the Financial Accounting Standards Board, or FASB, the U.S. Securities and Exchange Commission, or SEC, and various bodies formed to promulgate and interpret appropriate accounting principles. A change in these principles or interpretations could have a significant effect on our reported financial results, and could affect the reporting of transactions completed before the announcement of a change.

For example, in January 2016, the FASB issued Accounting Standards Update No. (ASU) 2016-01, "Recognition and Measurement of Financial Assets and Financial Liabilities." Amendments under ASU 2016-01, among other items, require that all equity investments in unconsolidated entities (other than those accounted for using the equity method of accounting), such as our investment in Sartorius AG, will be measured at fair value through earnings. The impact of adoption of ASU 2016-01 in the first quarter of 2018 materially impacted our Condensed Consolidated Statements of Income due to our investment in Sartorius AG and this impact may continue in future periods.

Also for example, in February 2016, the FASB issued ASU 2016-02, "Leases," which requires, among other items, lease accounting to recognize most leases as assets and liabilities on the balance sheet. We adopted ASU 2016-02 on a modified retrospective basis effective January 1, 2019 with practical expedients. Where we act as a lessee, the adoption of the standard resulted in material additions to the balance sheet for right-of-use assets and the associated liabilities. Where we act as a lessor in reagent rental arrangements, there was an insignificant impact to our condensed consolidated financial statements.

Our reported financial results may be materially affected by changes in the market value of our investment in Sartorius AG.

Changes in the market value of our investment in Sartorius AG may continue to materially impact our Consolidated Statements of Income and other financial statements. A decline in the market value of our investment in Sartorius AG could result in significant losses due to write-downs in the value of the equity securities. An increase in the market value of our investment in Sartorius AG could result in a significant and favorable impact to net income independent of the actual operating performance of our business. For example, net income for the third quarter of 2019 was significantly and unfavorably impacted by recognition, on the income statement, of a decline in the fair market value of equity securities of $390.6 million, primarily related to the holdings of our investment in Sartorius AG. Net income for the third quarter of 2018 was also significantly and favorably impacted by recognition, on the income statement, of an increase in the fair market value of equity securities of $318.0 million, primarily related to the holdings of our investment in Sartorius AG.

Our share price may change significantly based upon changes in the market valuation of Sartorius AG, and such change may be unrelated to the actual performance of our business. Non-operating income for a period may be significantly impacted by the timing of dividends paid by Sartorius AG, particularly in comparison to prior year periods.

We may incur losses in future periods due to write-downs in the value of financial instruments.

We have positions in a variety of financial instruments including asset backed securities and other similar instruments. Financial markets are volatile and the markets for these securities can be illiquid. The value of these securities will continue to be impacted by external market factors including default rates, changes in the value of the underlying property, such as residential or commercial real estate, rating agency actions, the prices at which observable market transactions occur and the financial strength of various entities, such as financial guarantors who provide insurance for the securities. Should we need to convert these positions to cash, we may not be able to sell these instruments without significant losses due to current debtor financial conditions or other market considerations.

We also have positions in equity securities, including our investment in Sartorius AG. Financial markets are volatile and the markets for these equity securities can be illiquid as well. A decline in the market value of our investments in equity securities that we own could result in significant losses due to write-downs in the value of the equity securities. In addition, if we need to convert these positions to cash, we may not be able to sell these equity securities without significant losses.

Environmental, health and safety regulations and enforcement proceedings may negatively impact our business, results of operations and financial condition.

Our operations are subject to federal, state, local and foreign environmental laws and regulations that govern such activities as transportation of goods, emissions to air and discharges to water, as well as handling and disposal practices for solid, hazardous and medical wastes. In addition to environmental laws that regulate our operations, we are also subject to environmental laws and regulations that create liability and clean-up responsibility for spills, disposals or other releases of hazardous substances into the environment as a result of our operations or otherwise impacting real property that we own or operate. The environmental laws and regulations also subject us to claims by third parties for damages resulting from any spills, disposals or releases resulting from our operations or at any of our properties. We must also comply with various health and safety regulations in the United States and abroad in connection with our operations.

We may in the future incur capital and operating costs to comply with currently existing laws and regulations, and possible new statutory enactments, and these expenditures may be significant. We have incurred, and may in the future incur, fines related to environmental matters and/or liability for costs or damages related to spills or other releases of hazardous substances into the environment at sites where we have operated, or at off-site locations where we have sent hazardous substances for disposal. We cannot assure you, however, that such matters or any future obligations to comply with environmental or health and safety laws and regulations will not adversely affect our business, results of operations or financial condition.

Our debt may restrict our future operations.

We have substantial debt and have the ability to incur additional debt. As of September 30, 2019, we had approximately $439.6 million of outstanding indebtedness. In addition, we have a revolving credit facility that provides for up to $200.0 million, $0.2 million of which has been utilized for domestic standby letters of credit. Our incurrence of substantial amounts of debt may have important consequences. For instance, it could:


•	make it more difficult for us to satisfy our financial obligations, including those relating to our outstanding debt;


•	require us to dedicate a substantial portion of our cash flow from operations to the payment of interest and principal due under our debt, which will reduce funds available for other business purposes;


•	increase our vulnerability to general adverse economic and industry conditions;


•	limit our flexibility in planning for, or reacting to, changes in our business and the industries in which we operate;


•	place us at a competitive disadvantage compared with some of our competitors that have less debt; and


•	limit our ability to obtain additional financing required to fund working capital and capital expenditures and for other general corporate purposes.

Our existing credit facility and the terms of our other debt instruments, including agreements we may enter in the future, contain or will contain covenants imposing significant restrictions on our business. These restrictions may affect our ability to operate our business and may limit our ability to take advantage of potential business opportunities as they arise. These covenants place restrictions on our ability to, among other things: incur additional debt; acquire other businesses or assets through merger or purchase; create liens; make investments; enter into transactions with affiliates; sell assets; in the case of some of our subsidiaries, guarantee debt; and declare or pay dividends, redeem stock or make other distributions to stockholders. Our existing credit facility also requires that we comply with certain financial ratios, including a maximum consolidated leverage ratio test and a minimum consolidated interest coverage ratio test.

Our ability to comply with these covenants may be affected by events beyond our control, including prevailing economic, financial and industry conditions. The breach of any of these restrictions could result in a default. An event of default under our debt agreements would permit some of our lenders to declare all amounts borrowed from them to be due and payable, together with accrued and unpaid interest. In addition, acceleration of our other indebtedness may cause us to be unable to make interest payments on our outstanding notes and repay the principal amount of our outstanding notes or may cause the future subsidiary guarantors, if any, to be unable to make payments under the guarantees.

We are subject to healthcare laws and regulations and could face substantial penalties if we are unable to fully comply with such laws.

We are subject to healthcare regulation and enforcement by both the U.S. federal government and the U.S. states and foreign governments in which we conduct our business. These healthcare laws and regulations include, for example:

•

the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from soliciting, receiving, offering or providing remuneration, directly or indirectly, in return for or to induce either the referral of an individual for, or the purchase order or recommendation of, any item or services for which payment may be made under a federal healthcare program such as the Medicare and Medicaid programs;

•

U.S. federal false claims laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payors that are false or fraudulent. In addition, the U.S. federal government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the false claims statutes;


•	the U.S. Physician Payment Sunshine Act, which requires certain manufacturers of drugs, biologics, devices and medical supplies to record any transfers of value to U.S. physicians and U.S. teaching hospitals;


•	the Health Insurance Portability and Accountability Act ("HIPAA"), as amended by the Health Information Technology for Economic and Clinical Health Act, which governs the conduct of certain electronic healthcare transactions and protects the security and privacy of protected health information; and


•	state or foreign law equivalents of each of the U.S. federal laws above, such as anti-kickback and false claims laws, which may apply to items or services reimbursed by any third-party payor, including commercial insurers.

These laws will continue to impose administrative, cost and compliance burdens on us. The shifting compliance environment and the need to build and maintain robust systems to comply with multiple jurisdictions with different compliance and/or reporting requirements increases the possibility that a healthcare company may violate one or more of these requirements. In addition, any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management’s attention from the operation of our business. If our operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to penalties, including civil and criminal penalties, damages, fines, exclusion from the Medicare and Medicaid programs, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business, results of operations and financial condition.

Regulations related to “conflict minerals” could adversely impact our business.

As part of the Dodd-Frank Wall Street Reform and Consumer Protection Act, the SEC adopted disclosure requirements regarding the use of certain minerals, known as conflict minerals, which are mined from the Democratic Republic of Congo (DRC) and adjoining countries, as well as procedures regarding a manufacturer's efforts to identify the sourcing of such minerals and metals produced from those minerals. In March and April 2017, the European Parliament and the European Council formally approved a conflict minerals regulation, and the requirements will become effective starting in January 2021. We have incurred, and will continue to incur, additional costs in order to comply with the SEC’s disclosure requirements. In addition, we might incur further costs due to possible changes to our products, processes, or sources of supply as a consequence of our due diligence activities. As our supply chain is complex, we may not be able to sufficiently verify the origins of the specified minerals used in our products through our due diligence procedures, which may harm our reputation. In addition, we may encounter challenges to satisfy those customers who require that all of the components of our products be certified as “DRC conflict free”, which could place us at a competitive disadvantage if we do not do so. We filed our report for the calendar year 2018 with the SEC on May 3, 2019.

Risks related to our common stock

A significant majority of our voting stock is held by the Schwartz family, which could lead to conflicts of interest.

We have two classes of voting stock: Class A Common Stock and Class B Common Stock. With a few exceptions, holders of Class A and Class B Common Stock vote as a single class. When voting as a single class, each share of Class A Common Stock is entitled to one-tenth of a vote, while each share of Class B Common Stock has one vote. In the election or removal of directors, the classes vote separately and the holders of Class A Common Stock are entitled to elect 25% of the Board of Directors, with holders of Class B Common Stock electing the remaining directors.

As a result of the Schwartz family's ownership of our Class A and Class B Common Stock, they are able to elect a majority of our directors, effect fundamental changes in our direction and control matters affecting us, including the determination of business opportunities that may be suitable for our company. The Schwartz family may exercise its control over us according to interests that are different from other investors’ or debtors’ interests. In particular, this concentration of ownership and voting power may have the effect of delaying or preventing a change in control of our company.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

In November, 2017, the Board of Directors authorized a new share repurchase program, granting Bio-Rad authority to repurchase, on a discretionary basis, up to $250.0 million of outstanding shares of our common stock. Repurchases may be made at management's discretion from time to time on the open market or through privately negotiated transactions. This authorization has no expiration.

The following table contains information on the shares of our common stock that we purchased or otherwise acquired during the three months ended September 30, 2019.



Period	Total Number of Shares Purchased		Average Price Paid per Share		Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs		Maximum Number (or Approximate Dollar Value) of Shares that May yet be Purchased Under the Plans or Programs (in millions)
July 1 to July 31, 2019	—		$	—	—		$	186.1
August 1 to August 31, 2019	14,745	Class A	$	339.05	14,745	Class A	$	181.1
September 1 to September 30, 2019	—		$	—	—		$	181.1

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

None.

Item 6. Exhibits

(a) Exhibits

The following documents are filed as part of this report:



Exhibit No.

31.1	Chief Executive Officer Section 302 Certification

31.2	Chief Financial Officer Section 302 Certification

32.1	Chief Executive Officer Certification pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

32.2	Chief Financial Officer Certification pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

101.INS	The instance document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document.

101.SCH	Inline XBRL Taxonomy Extension Schema Document

101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document

101.LAB	Inline XBRL Taxonomy Extension Labels Linkbase Document

101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase Document



104.1	The cover page Interactive Data File is formatted in Inline XBRL and is contained in Exhibits 101

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereto duly authorized.



BIO-RAD LABORATORIES, INC.
(Registrant)

Date:	November 1, 2019	/s/ Norman Schwartz
		Norman Schwartz, Chairman of the Board,
		President and Chief Executive Officer

Date:	November 1, 2019	/s/ Ilan Daskal
		Ilan Daskal, Executive Vice President,
		Chief Financial Officer